[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2515
1. Haroon M, Kwong WY, Cantwell B, Walker F: A case of cetuximab-related tumour lysis syndrome in metastatic rectal carcinoma. NDT Plus; 2010 Jun;3(3):271-272

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 60-year-old man was diagnosed with a moderately differentiated adenocarcinoma in November 2006.
  • The computed tomography (CT), magnetic resonance imaging (MRI) and whole-body positron emission tomography-CT (PET-CT) scan showed the presence of multiple liver metastases which were confined to its right lobe.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2406-8 [18467734.001]
  • [Cites] Ann Oncol. 2005 May;16 Suppl 4:iv50-55 [15923430.001]
  • [Cites] J Natl Cancer Inst. 1998 May 6;90(9):675-84 [9586664.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2643-8 [17363584.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):299-304 [11208819.001]
  • [Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S16-22 [11597400.001]
  • (PMID = 28657052.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Ramia JM, Villar J, Palomeque A, Muffak K, Mansilla A, Garrote D, Ferrón JA: [Duodenal adenocarcinoma]. Cir Esp; 2005 Apr;77(4):208-12
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Duodenal adenocarcinoma].
  • [Transliterated title] Adenocarcinoma de duodeno.
  • INTRODUCTION: Duodenal adenocarcinoma is an infrequent neoplasm.
  • Consequently, there are no large series that would allow conclusions to be reached on its diagnosis and treatment.
  • PATIENTS AND METHOD: A retrospective study (1999-2003) of five patients diagnosed with duodenal adenocarcinoma in our service was performed.
  • All patients underwent gastrointestinal endoscopy with biopsy, which revealed adenocarcinoma.
  • In all patients, the preoperative diagnosis was correct.
  • A decision not to perform surgery was made in one patient with liver metastases.
  • CONCLUSION: Duodenal adenocarcinoma is an infrequent tumor that is associated with various diseases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Duodenal Neoplasms / diagnosis. Duodenal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420919.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


3. Molina Granados JF, Escribano Fernández J, Vida Pérez L, Barrena Baena P: [Biliary obstruction due to adenocarcinoma of the ampulla of Vater ten years after orthotopic liver transplantation]. Radiologia; 2009 Nov-Dec;51(6):610-3
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biliary obstruction due to adenocarcinoma of the ampulla of Vater ten years after orthotopic liver transplantation].
  • [Transliterated title] Obstrucción biliar por adenocarcinoma de la papila de Vater en un paciente con trasplante hepático ortotópico.
  • The main causes of death in patients with liver transplants are derived from the graft itself.
  • Given the increased survival in this group of patients, the rate of de novo neoplasms in other locations is increasing.
  • We present the case of a 60-year-old man who underwent orthotopic liver transplantation 10 years earlier for terminal cirrhosis caused by hepatitis B.
  • Imaging studies showed dilation of the intra- and extra-hepatic bile ducts with no evidence of lithiasis, anastomotic stenosis, or other biliary complications that are common in patients with liver transplants.
  • The definitive diagnosis was reached by endoscopic retrograde cholangiopancreatography.
  • Adenocarcinoma of the ampulla of Vater should be considered among the causes of biliary obstruction in patients with orthotopic liver transplants.
  • [MeSH-major] Adenocarcinoma / complications. Ampulla of Vater. Cholestasis / etiology. Common Bile Duct Neoplasms / complications. Liver Transplantation / adverse effects

  • Genetic Alliance. consumer health - TEN.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19836032.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Dechaphunkul A, Kanngurn S, Dechsukhum C, Tanutit P, Khow-Ean U, Sunpaweravong P: The significance of galectin-3 immunohistochemistry, clinical characteristics and liver imaging in differentiating intrahepatic cholangiocarcinoma from adenocarcinoma liver metastasis. J Med Assoc Thai; 2010 May;93(5):523-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of galectin-3 immunohistochemistry, clinical characteristics and liver imaging in differentiating intrahepatic cholangiocarcinoma from adenocarcinoma liver metastasis.
  • OBJECTIVE: To identify differences of Galectin-3 (Gal-3) immunostaining, clinical profiles, and images in patients with intrahepatic cholangiocarcinoma (IHC) and adenocarcinoma liver metastasis, and be able to recognize these parameters as diagnostic tools for differentiating these two diseases.
  • MATERIAL AND METHOD: Histological slides from patients with IHC and adenocarcinoma liver metastasis were reviewed Immunohistochemical staining for Gal-3, Cytokeratin-7 (CK-7), and Cytokeratin-20 (CK-20) was performed and the results categorized.
  • Moreover clinical characteristics and liver images of the patients were reviewed.
  • RESULTS: Eighty-two patients were evaluated, 31 IHC and 51 adenocarcinoma liver metastasis.
  • Finding showed that 86% of them were IHC whereas only 14% were in adenocarcinoma liver metastasis.
  • All patients with liver images showing a single lesion, located at central site, and having intrahepatic duct dilatation were IHC.
  • On the other hand, 77% of patients with liver imaging showing multiple liver masses, located at peripheral site and having no intrahepatic duct dilatation were adenocarcinoma liver metastasis while only 23% were in IHC.
  • CONCLUSION: Adding Gal-3 to CK-7 and CK-20 immunohistochemistry has benefits to differentiate IHC from adenocarcinoma liver metastasis.
  • Furthermore, liver imaging profiles also give benefits for differentiating between these two diseases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Bile Duct Neoplasms / diagnosis. Cholangiocarcinoma / diagnosis. Galectin 3 / metabolism. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Bile Ducts, Intrahepatic / metabolism. Bile Ducts, Intrahepatic / pathology. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Keratin-20 / metabolism. Keratin-7 / metabolism. Liver / radiography. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524437.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


5. Vila Auli B, Pérez García D, Fernández Rodríguez C, Bañuls Polo P, Marín Pardo J: [Hepatopulmonary syndrome in a patient with adenocarcinoma of the colon metastatic to the liver and no apparent chronic liver disease]. Arch Bronconeumol; 2006 Sep;42(9):484-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatopulmonary syndrome in a patient with adenocarcinoma of the colon metastatic to the liver and no apparent chronic liver disease].
  • [Transliterated title] Síndrome hepatopulmonar en paciente con adenocarcinoma de colon con metástasis hepáticas y sin hepatopatía crónica conocida.
  • Hepatopulmonary syndrome consists of a clinical triad: arterial blood deoxygenation, intrapulmonary vasodilation, and liver disease.
  • We describe the case of a patient with hepatopulmonary syndrome and adenocarcinoma of the colon with metastases to a previously healthy liver.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Hepatopulmonary Syndrome / etiology. Liver Neoplasms / secondary
  • [MeSH-minor] Colon / pathology. Colon / radiography. Colonoscopy. Humans. Liver / pathology. Liver / radiography. Liver Function Tests. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17040663.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


6. Eickhoff A, Spiethoff A, Hartmann D, Jakobs R, Weickert U, Schilling D, Eickhoff JC, Bohrer MH, Riemann JF: [Space-occupying lesions in the liver: incidence of adenocarcinoma metastases of unknown primary site]. Dtsch Med Wochenschr; 2007 Feb 23;132(8):369-74
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Space-occupying lesions in the liver: incidence of adenocarcinoma metastases of unknown primary site].
  • [Transliterated title] Unklare hepatische Raumforderungen: Häufigkeit von Adenokarzinom-Metastasen eines unbekannten Primärtumors.
  • BACKGROUND AND OBJECTIVE: The diagnostic approach to newly detected space-occupying lesions in the liver can be difficult and a histogenetic classification of the primary tumor is impossible in some cases.
  • The incidence of this diagnosis depends on the clinical and histochemical methods used.
  • It was the main aim of this study to analyze the true incidence of adenocarcinoma metastases of the liver with an unknown primary cancer after application of a standardized protocol of clinical and immunhistochemical diagnostic tests and a long-term follow-up.
  • PATIENTS AND METHODS: Between January 2000 and January 2003 127 consecutive patients underwent diagnostic ultrasound-guided biopsy of a space-occupying lesion in the liver.
  • Primary tumors of the liver were found in 21 cases and non-hepatocellular tumors (metastases) were documented in 106 patients, 82 of the latter (77%) had metastases of an adenocarcinoma.
  • The further diagnostic approach was based on histochemistry, immunhistochemistry and imaging techniques, making possible a full diagnosis of primary tumor in a further 59 (72%) cases.
  • Thus the incidence of an adenocarcinoma of the liver of unknown primary site was 23 of 127 cases (18%).
  • CONCLUSIONS: Although there is a wide variety of modern diagnostic methods today, the histogenetic classification of hepatic metastases is not always possible.
  • [MeSH-major] Adenocarcinoma / secondary. Liver Neoplasms / secondary. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Incidence. Karnofsky Performance Status. Liver / pathology. Liver / ultrasonography. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17299675.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Sakai M, Oguri T, Sato S, Hattori N, Bessho Y, Achiwa H, Maeda H, Niimi T, Ueda R: Spontaneous hepatic rupture due to metastatic tumor of lung adenocarcinoma. Intern Med; 2005 Jan;44(1):50-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous hepatic rupture due to metastatic tumor of lung adenocarcinoma.
  • A 64-year-old man diagnosed as lung adenocarcinoma with hepatic tumor was admitted to our hospital.
  • He carried the hepatitis B virus but was negative for PIVKA-II and alpha-fetoprotein, and hence we diagnosed a case of stage IV lung adenocarcinoma.
  • We diagnosed hemorrhagic ascites due to spontaneous rupture of the liver tumor.
  • Hemorrhagic ascites due to metastatic liver tumor is rare and the sudden onset of abdominal symptoms is an indicator of rupture.
  • [MeSH-major] Adenocarcinoma / secondary. Liver Diseases / etiology. Liver Neoplasms / complications. Liver Neoplasms / secondary. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15704663.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Wang L, Vuolo M, Suhrland MJ, Schlesinger K: HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates. Acta Cytol; 2006 May-Jun;50(3):257-62
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates.
  • OBJECTIVE: To investigate immunohistochemical staining of hepatocyte paraffin-1 (HepPar1), alpha-fetoprotein (AFP), polyclonal carcinoembryonic antigen (pCEA), monoclonal CEA (mCEA), MOC-31 and CD10 for differential diagnosis of hepatocellular carcinoma (HCC) from metastatic adenocarcinoma (MA) on fine needle aspiration biopsy (FNAB).
  • We suggest using HepPar1, pCEA, CD10, MOC-31 and mCEA as a panel for distinguishing HCC from MA in liver FNAB.
  • [MeSH-major] Adenocarcinoma / secondary. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / pathology. Liver / pathology. Liver Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Biopsy, Fine-Needle. Carcinoembryonic Antigen / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Neprilysin / analysis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780018.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


9. Ghittoni G, Caturelli E, Viera FT: Intrabile duct metastasis from colonic adenocarcinoma without liver parenchyma involvement: contrast enhanced ultrasonography detection. Abdom Imaging; 2010 Jun;35(3):346-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrabile duct metastasis from colonic adenocarcinoma without liver parenchyma involvement: contrast enhanced ultrasonography detection.
  • It is well-known that biliary duct invasion with intraluminal growth is one of the developmental patterns of primary liver tumors, and macroscopic intrabiliary growth of liver metastases in colorectal cancer is found with high frequency.
  • We describe the first recorded case of a metastasis from colorectal cancer involving solely the common hepatic biliary duct, without invasion of contiguous liver parenchyma.
  • A correct diagnosis was obtained by means of contrast enhanced ultrasound and ultrasound-guided fine needle aspiration biopsy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Hepatic Duct, Common / pathology. Ultrasonography, Doppler, Color
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Cholangiography. Common Bile Duct / pathology. Common Bile Duct / ultrasonography. Humans. Image Enhancement. Lymphatic Metastasis. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19294464.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Eigenbrod T, Kullmann F, Klebl F: Resection of small bowel adenocarcinoma liver metastasis combined with neoadjuvant and adjuvant chemotherapy results in extended disease-free period--a case report. Int J Gastrointest Cancer; 2006;37(2-3):94-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of small bowel adenocarcinoma liver metastasis combined with neoadjuvant and adjuvant chemotherapy results in extended disease-free period--a case report.
  • Small bowel adenocarcinoma (SBA) is a very rare tumor entity but occurs in up to 5% of patients suffering from familiar adenomatous polyposis (FAP).
  • Because of nonspecific symptoms, diagnosis is usually made with delay, which contributes to high rates of metastatic disease at the time of diagnosis.
  • In October 2001, a 51-year-old woman with attenuated FAP, that had total proctocolectomy in 1994 was diagnosed with a jejunal adenocarcinoma.
  • Because a computed tomography (CT) scan in April 2002 revealed multiple liver metastases, chemotherapy with nine cycles FOLFOX6 was initiated.
  • This solitary residual liver metastasis was resected in January 2004.
  • To date, more than 3 years after liver resection, the patient is still in complete remission and undergoes regular restaging investigations.
  • Resection of liver metastases from SBA combined with neoadjuvant and adjuvant chemotherapy can result in extended disease-free survival and should undergo further investigation.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hepatectomy. Ileal Neoplasms / therapy. Jejunal Neoplasms / therapy. Liver Neoplasms / therapy. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17827529.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


11. Gamelin E, Mineur L, Chevelle C, Cailleux P, Martin L, Bastit L, Roullet B, Hasbini A, Savary J, Cellier P: Neoadjuvant radiotherapy ± tegafur-uracil plus leucovorin in rectal adenocarcinoma: Final results of a French multicenter phase III study. J Clin Oncol; 2009 May 20;27(15_suppl):4104

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant radiotherapy ± tegafur-uracil plus leucovorin in rectal adenocarcinoma: Final results of a French multicenter phase III study.
  • : 4104 Background: Neoadjuvant chemoradiotherapy (CRT) with tegafur-uracil (UFT) plus leucovorin (LV) has shown promising results in patients with rectal adenocarcinoma (RAC).
  • 172 pts underwent surgery (97.2%), 5 pts were not resected (4 liver and 1 lung metastases plus 1 CVA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961187.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Feliu J, Safont M, Salud A, Losa F, García-Girón C, Bosch C, Escudero P, López R, Madroñal C, González-Barón M: Phase II study to evaluate the efficacy of capecitabine combined with bevacizumab as first-line treatment in elderly patients with advanced or metastatic colorectal adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):4119

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study to evaluate the efficacy of capecitabine combined with bevacizumab as first-line treatment in elderly patients with advanced or metastatic colorectal adenocarcinoma.
  • : 4119 Background: Colorectal adenocarcinoma is the most common cancer in subjects over 70 years old.
  • The aim of the present study is to evaluate the overall response rate in that patient's population who presents colorectal adenocarcinoma and are treated with the combination of capecitabine+BVZ.
  • Metastases were detected in liver (84.7%), lung (45.8%), local/regional (18.6%) and other locations (5.1%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961217.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Fine R, Moorer G, Sherman W, Chu K, Maurer M, Chabot J, Postolov I, Prowda J, Schreibman S, Levitz J: Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4623

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with histologically confirmed metastatic adenocarcinoma of the pancreas, median age 60, 63% male, ECOG PS 0-2, received capecitabine 1500mg/m2/day total orally in divided doses, days 1 thru 14, gemcitabine 750mg/m2 IV over 75 minutes followed by docetaxel 30mg/m2 IV on days 4 and 11 on a 21 day cycle.
  • 35 patients (85%) had liver metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964215.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Maximous D, Abdel-Wanis ME, Aboziada MA, El-Sayed MI, Abd-Elsayed AA: Preoperative gemcitabine based chemoradiotherapy in locally advanced nonmetastatic pancreatic adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15677

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative gemcitabine based chemoradiotherapy in locally advanced nonmetastatic pancreatic adenocarcinoma.
  • Out of 8 patients who underwent radical surgical resection, only one patient developed local recurrence and simultaneous liver metastasis during the follow up period.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962829.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Kobayashi K, Inoue A, Maemondo M, Sugawara S, Isobe H, Oizumi S, Saijo Y, Gemma A, Morita S, Hagiwara K, Nukiwa T: First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group. J Clin Oncol; 2009 May 20;27(15_suppl):8016

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Their characteristics were well balanced between arms: median age=65 years; 64% female; 77% Stage IV; 93% adenocarcinoma, 61% non-smoker.
  • There were several differences in toxicities between Arm A and Arm B (grade 4 neutropenia: 1% vs. 29%, grade 3-4 liver dysfunction: 24% vs. 1%, grade 3 neuropathy: 0% vs. 5%, respectively, p<0.01).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962807.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Larbaoui B: Preoperative concomitant chemoradiotherapy with capecitabine in locally advanced rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15134

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Inclusion criteria: rectal adenocarcinoma <12 cms from anal verge, clinical stage T3-4, adequate renal, hematological and liver function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960909.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Djellali L, Larbaoui B, Boukerche A, Ghazi S, Chaiba I, Meziane N, Yekrou D, Youcef DF: Preoperative concomitant chemoradiotherapy with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secondary endpoint was sphincter preservation and toxicity Methods: Inclusion criteria: rectal adenocarcinoma <12 cms from anal verge, clinical stage T3-4, adequate renal, hematological and liver function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964340.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Cardona Zorrilla AF, Moran T, Reguart N, Porta R, Queralt C, Cardenal F, Carrasco-Chaumel E, Massuti B, Taron M, Rosell R: Characteristics and outcomes of non-small cell lung cancer (NSCLC) patients (pts) carrying epidermal growth factor receptor (EGFR) mutations who progress after initial erlotinib (E) response. J Clin Oncol; 2009 May 20;27(15_suppl):8064

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Pts mean age was 59±12.5 years; 65% females; 94% never-smokers; 54 adenocarcinoma.
  • 35 pts (63%) were PS ≤2; main metastasis sites were lung (39/71%), bone (21/38%) and liver (10/18%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962639.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Yamasaki T, Nebiki H, Sasaki E, Kurai O: Successful treatment of duodenal adenocarcinoma with multiple liver metastases by S-1 + irinotecan (CPT-11). Clin J Gastroenterol; 2009 Aug;2(4):287-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of duodenal adenocarcinoma with multiple liver metastases by S-1 + irinotecan (CPT-11).
  • Unresectable duodenal adenocarcinoma excluding the ampullary region is rare, and no standard chemotherapy has been defined for this disease.
  • We present herein a case of duodenal adenocarcinoma with liver metastases.
  • Gastroduodenal endoscopy revealed an ulcerative lesion on the upper wall of the duodenal bulb, and biopsy specimens showed well-differentiated adenocarcinoma.
  • Computed tomography and ultrasonography showed multiple liver metastases.
  • Tumor markers subsequently normalized, and liver metastases were diminished.
  • The patient died due to hepatic failure, with an overall survival of 15 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 26192427.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Chemotherapy / Duodenal cancer / Irinotecan / Liver metastases / S-1
  •  go-up   go-down


20. Lin CW, Hsu CC, Chang HC, Sun YC, Sun PL, Hsu CY, Perng DS: Hepatoid adenocarcinoma of the stomach with liver metastasis mimicking hepatocellular carcinoma: a case report. Cases J; 2009;2:6317

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid adenocarcinoma of the stomach with liver metastasis mimicking hepatocellular carcinoma: a case report.
  • INTRODUCTION: Hepatoid adenocarcinoma is a special type of extrahepatic alpha-fetoprotein-producing adenocarcinoma, which has a morphologic similarity to hepatocellular carcinoma.
  • We report a patient with underlying hepatitis B virus infection and hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma.
  • CASE PRESENTATION: We present the case of a 56-year-old Chinese female with underlying hepatitis B virus infection, who was found to have multiple hepatic tumors by abdominal ultrasound and an elevated level of serum alpha-fetoprotein.
  • However, the tumor histology of the stomach and liver revealed glandular adenocarcinoma with hepatoid foci.
  • The final diagnosis is hepatoid adenocarcinoma of the stomach with liver metastasis.
  • CONCLUSION: Hepatoid adenocarcinoma is an aggressive tumor with liver metastasis being the first clinical manifestation of the neoplasm.
  • Hepatoid adenocarcinoma of the stomach with liver metastasis should be considered in older patients with elevated serum alpha-fetoprotein and multiple hepatic tumors with underlying chronic liver disease.
  • An upper gastrointestinal endoscopy should be performed to exclude the possibility of hepatoid adenocarcinoma originating from the stomach to avoid potential misdiagnosis and inappropriate therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1985 Aug 15;56(4):840-8 [2410093.001]
  • [Cites] Presse Med. 1970 Jun 6;78(28):1277-8 [5426134.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2165-73 [6091861.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1827-35 [7689918.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1050-4 [7692729.001]
  • [Cites] Histopathology. 1997 Jul;31(1):47-54 [9253624.001]
  • [Cites] Mayo Clin Proc. 1997 Dec;72(12):1154-60 [9413299.001]
  • [Cites] Hepatology. 2000 Aug;32(2):200-4 [10915724.001]
  • [Cites] Am J Clin Pathol. 2001 May;115(5):689-94 [11345832.001]
  • [Cites] Gastric Cancer. 2001;4(1):43-52 [11706627.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):137-44 [12591966.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1302-12 [14508391.001]
  • [Cites] Pathology. 2005 Jun;37(3):211-5 [16175893.001]
  • [Cites] Acta Gastroenterol Belg. 2006 Jul-Sep;69(3):330-7 [17168134.001]
  • [Cites] J Dig Dis. 2007 Feb;8(1):23-8 [17261131.001]
  • (PMID = 19918575.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2769285
  •  go-up   go-down


21. Cleary JM, Tanabe KT, Lauwers GY, Zhu AX: Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist; 2009 Nov;14(11):1095-105
Hazardous Substances Data Bank. CETUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver.
  • Colorectal cancer patients with isolated liver metastasis are potentially cured with surgical resection.
  • Recent advances in systemic chemotherapy have increased the ability to convert unresectable metastatic liver lesions to resectable lesions.
  • In this review, we summarize the current clinical experience with these hepatic toxicities and discuss the role they play in determining postoperative morbidity.
  • Finally, we give specific clinical examples of how multidisciplinary teams can best manage patients receiving preoperative chemotherapy for potentially resectable liver metastases.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / adverse effects. Colorectal Neoplasms / drug therapy. Drug-Induced Liver Injury / etiology. Liver Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19880627.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 2S9ZZM9Q9V / Bevacizumab; PQX0D8J21J / Cetuximab
  • [Number-of-references] 74
  •  go-up   go-down


22. Goldstein NS, Bosler D: An approach to interpreting immunohistochemical stains of adenocarcinoma in small needle core biopsy specimens: the impact of limited specimen size. Am J Clin Pathol; 2007 Feb;127(2):273-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An approach to interpreting immunohistochemical stains of adenocarcinoma in small needle core biopsy specimens: the impact of limited specimen size.
  • Interpreting immunohistochemical stains of metastatic adenocarcinoma in small needle core biopsy specimens is not always straightforward.
  • We studied the effects of small specimen size on immunohistochemical stain results in 20 colorectal adenocarcinoma hepatic resection specimens stained with cytokeratin (CK)7 and CK20.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle / methods. Colorectal Neoplasms / pathology. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Biospecimen Research Database. Biospecimen Research Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17210515.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


23. Schima W, Ba-Ssalamah A, Kölblinger C, Kulinna-Cosentini C, Puespoek A, Götzinger P: Pancreatic adenocarcinoma. Eur Radiol; 2007 Mar;17(3):638-49
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma.
  • Adenocarcinoma is the most common malignant pancreatic tumor, affecting the head of the pancreas in 60-70% of cases.
  • By the time of diagnosis, at least 80% of tumors are unresectable.
  • Helical computed tomography (CT) is very effective in detecting and staging adenocarcinoma, with a sensitivity of up to 90% for detection and an accuracy of 80-90% for staging, but it has limitations in detecting small cancers.
  • Moreover, it is not very accurate for determining nonresectability because small liver metastases, peritoneal carcinomatosis, and subtle signs of vascular infiltration may be missed.
  • MDCT has been found to be at least equivalent to contrast-enhanced magnetic resonance imaging (MRI) for detecting adenocarcinoma.
  • It is the technique of choice for image-guided biopsy if a histologic diagnosis is required for further therapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Pancreatic Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Contrast Media. Endosonography. Humans. Magnetic Resonance Imaging. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17021700.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 65
  •  go-up   go-down


24. Stern AW, Velguth KE, D'Agostino J: Metastatic ductal adenocarcinoma in a Western Hognose snake (Heterodon nasicus). J Zoo Wildl Med; 2010 Jun;41(2):320-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic ductal adenocarcinoma in a Western Hognose snake (Heterodon nasicus).
  • Histologically, the mass was composed of tubules of columnar to flattened neoplastic cells with an abundant stroma and moderate cellular atypia consistent with a scirrhous adenocarcinoma, likely ductal in origin, given the location of the neoplastic mass.
  • Necropsy and histopathologic examination confirmed metastasis of the previously removed adenocarcinoma to the liver, right kidney, and large intestine.
  • [MeSH-major] Adenocarcinoma / veterinary. Snakes
  • [MeSH-minor] Animals. Female. Intestinal Neoplasms / secondary. Kidney Neoplasms / secondary. Liver Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20597225.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Katabi N: Neoplasia of gallbladder and biliary epithelium. Arch Pathol Lab Med; 2010 Nov;134(11):1621-7
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Diagnosis of biliary neoplasia can be challenging but is essential for the appropriate clinical management of patients.
  • Therefore, it is important to recognize the morphologic features of the biliary neoplasms to report a correct diagnosis. OBJECTIVES:.
  • (1) To discuss the differential diagnosis of dysplasia in the gallbladder and differentiate dysplasia from reactive atypia and invasive carcinoma, (2) review the histologic features of adenoma and polypoid biliary lesions, (3) highlight the differential diagnosis of adenocarcinoma in liver biopsy, and (4) discuss the differential diagnosis of atypical biliary glandular lesions.
  • Careful examination of the histologic features of these lesions and familiarity with their morphology can help to achieve the correct diagnosis.
  • [MeSH-minor] Diagnosis, Differential. Humans. Metaplasia / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21043815.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


26. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL: Metastatic patterns in adenocarcinoma. Cancer; 2006 Apr 1;106(7):1624-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic patterns in adenocarcinoma.
  • The authors analyzed clinical data from a large number of patients with histologically confirmed, distant-stage adenocarcinoma to evaluate metastatic patterns.
  • RESULTS: Three primary tumors had single, dominant metastatic sites: ovary to abdominal cavity (91%), prostate to bone (90%), and pancreas to liver (85%).
  • The liver was the dominant metastatic site for gastrointestinal (GI) primary tumors (71% of patients), whereas bone and lung metastases were noted most frequently in non-GI primary tumors (43% and 29%, respectively).
  • In a study of combinations of liver, abdominal cavity, and bone metastases, 86% of prostate primary tumors had only bone metastases, 80% of ovarian primary tumors had only abdominal cavity metastases, and 74% of pancreas primary tumors had only liver metastases.
  • [MeSH-major] Adenocarcinoma / secondary. Algorithms. Neoplasm Metastasis. Registries / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16518827.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Sakata J, Wakai T, Shirai Y, Sakata E, Hasegawa G, Hatakeyama K: Humoral hypercalcemia complicating adenocarcinoma of the sigmoid colon: report of a case. Surg Today; 2005;35(8):692-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Humoral hypercalcemia complicating adenocarcinoma of the sigmoid colon: report of a case.
  • A 54-year-old woman was admitted with symptomatic hypercalcemia of 14.2 mg/dl and multiple hepatic metastases, 2 years after resection of sigmoid colon cancer.
  • The hypercalcemia was caused by the circulating parathyroid hormone-related peptide (PTHrP) produced by poorly differentiated adenocarcinoma in the liver.
  • [MeSH-major] Adenocarcinoma / complications. Hypercalcemia / etiology. Sigmoid Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034553.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein
  • [Number-of-references] 19
  •  go-up   go-down


28. Ambro CM, Humphreys TR, Lee JB: Epidermotropically metastatic pancreatic adenocarcinoma. Am J Dermatopathol; 2006 Feb;28(1):60-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermotropically metastatic pancreatic adenocarcinoma.
  • We describe an epidermotropically metastatic pancreatic mucinous ductal adenocarcinoma on the scalp.
  • The patient's history of pancreatic mucinous ductal adenocarcinoma and immunohistochemical staining pattern of carbohydrate antigen 19-9 (CA 19-9) confirmed the diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Carcinoma, Pancreatic Ductal / secondary. Pancreatic Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Biomarkers, Tumor / analysis. CA-19-9 Antigen / analysis. Humans. Liver Neoplasms / secondary. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16456328.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


29. Abrams JA: Chemoprevention of esophageal adenocarcinoma. Therap Adv Gastroenterol; 2008 Jul;1(1):7-18
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention of esophageal adenocarcinoma.
  • The incidence of esophageal adenocarcinoma (EAC) is rising rapidly in Western countries, and effective chemoprevention for this malignancy is lacking.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):72-5 [16391374.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):22-30 [8514038.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 15;87(4):265-73 [7707417.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1219-23 [17548688.001]
  • [Cites] J Am Coll Nutr. 2006 Apr;25(2):79-99 [16582024.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Chest. 2005 May;127(5):1658-66 [15888843.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2929-34 [9679948.001]
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):2120-8 [8903332.001]
  • [Cites] JAMA. 1995 Aug 9;274(6):474-7 [7629956.001]
  • [Cites] Am J Gastroenterol. 1989 Oct;84(10):1263-7 [2801676.001]
  • [Cites] Am J Physiol. 1986 Nov;251(5 Pt 1):G597-601 [3777167.001]
  • [Cites] Carcinogenesis. 2004 May;25(5):723-7 [14754873.001]
  • [Cites] Med J Aust. 2004 Apr 19;180(8):387-91 [15089728.001]
  • [Cites] Life Sci. 2004 Feb 6;74(12):1513-8 [14729400.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1670-7 [14724819.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):615-25 [12612900.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):60-7 [12105834.001]
  • [Cites] Eur J Cancer Prev. 2001 Aug;10(4):365-9 [11535879.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2753-60 [17691111.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 4;99(7):545-57 [17405999.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4220-9 [11751523.001]
  • [Cites] Int J Cancer. 2001 Feb 1;91(3):283-7 [11169948.001]
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):913-5 [9796637.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):126-34 [18187391.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8580-7 [17875697.001]
  • [Cites] Semin Cancer Biol. 2007 Oct;17(5):403-10 [17574861.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5176-82 [17785574.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2853-9 [16510608.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):859-61 [16189516.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2377-83 [16214920.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 7;90(1):57-62 [9428784.001]
  • [Cites] Aliment Pharmacol Ther. 1990 Apr;4(2):131-8 [2104080.001]
  • [Cites] IARC Sci Publ. 1991;(105):123-8 [1855835.001]
  • [Cites] Gastroenterology. 1988 Dec;95(6):1541-8 [2903111.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1915-9 [15026323.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):316-25 [14970280.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):883-90 [12621132.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] Am J Gastroenterol. 2002 Jan;97(1):22-6 [11808965.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1055-62 [11588131.001]
  • [Cites] Int J Cancer. 2000 Sep 1;87(5):750-4 [10925371.001]
  • [Cites] J Nutr. 2000 Feb;130(2):129-32 [10720158.001]
  • [Cites] Am J Gastroenterol. 2007 Jan;102(1):10-20 [17266684.001]
  • [Cites] Am J Cardiol. 2006 Jul 1;98(1):121-8 [16784934.001]
  • [Cites] Arch Surg. 2005 Dec;140(12):1204-9; discussion 1209 [16365243.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):327-35 [10419913.001]
  • [Cites] Gastroenterology. 2004 Jun;126(7):1692-9 [15188164.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2096-102 [12412162.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):633-40 [11874995.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):299-307 [11832445.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1391-9 [11729118.001]
  • [Cites] Gastroenterology. 2007 Oct;133(4):1198-209 [17919494.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Oct;5(10):1160-1166.e1 [17916544.001]
  • [Cites] Gut. 2007 Jul;56(7):906-17 [17185354.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Nov 1;24(9):1321-31 [17059513.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1271-83 [17030196.001]
  • [Cites] J Natl Cancer Inst. 2006 Aug 16;98(16):1158-61 [16912268.001]
  • [Cites] Nutr Cancer. 2006;54(1):148-56 [16800781.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 1;23(5):587-93 [16480397.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2559-66 [16380980.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):945-52 [16321762.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Oct;2(10):880-7 [15476151.001]
  • [Cites] Am J Gastroenterol. 2004 Feb;99(2):218-24 [15046208.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):34-9 [14744730.001]
  • [Cites] Carcinogenesis. 2003 Dec;24(12):1951-60 [12970071.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3486-91 [12960141.001]
  • [Cites] Gastroenterology. 2003 Jun;124(7):1758-66 [12806608.001]
  • [Cites] Gastroenterology. 1998 Aug;115(2):275-80 [9679032.001]
  • [Cites] Gut. 1996 Oct;39(4):574-9 [8944568.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1116-9 [8630885.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):1877-83 [15447744.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):487-96 [10702199.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2381-6 [17893868.001]
  • [Cites] BMC Gastroenterol. 2007;7:1 [17257428.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4975-82 [16651456.001]
  • [Cites] Carcinogenesis. 2005 Sep;26(9):1627-33 [15878911.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):740-3 [15767361.001]
  • [Cites] Ann Intern Med. 1998 Oct 1;129(7):517-24 [9758570.001]
  • [Cites] N Engl J Med. 1996 May 2;334(18):1150-5 [8602180.001]
  • [Cites] Br J Surg. 1987 Sep;74(9):774-6 [3664238.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Oct;287(4):G743-8 [15231484.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Int J Cancer. 2002 Dec 20;102(6):551-5 [12447994.001]
  • [Cites] Nutr Cancer. 2002;42(1):33-40 [12235648.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):860-8 [12115489.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 20;94(6):422-9 [11904314.001]
  • [Cites] Oncol Rep. 2007 Dec;18(6):1443-9 [17982628.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Jan 15;25(2):197-205 [17229243.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 15;23(6):727-33 [16556174.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):136-41 [16404367.001]
  • [Cites] Gut. 1998 Aug;43(2):216-22 [10189847.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4784-92 [15269153.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):885-7; author reply 887 [15173278.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 11):111-9 [12138405.001]
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):836-42 [11893796.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Jan;41(1):41-55 [11796231.001]
  • [Cites] Oncogene. 2001 Nov 29;20(55):7987-91 [11753681.001]
  • [Cites] Am J Gastroenterol. 2001 Apr;96(4):990-6 [11316217.001]
  • [Cites] Surgery. 2001 Mar;129(3):267-76 [11231454.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5767-72 [11059772.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Feb 15;27(4):321-6 [18047565.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G18-27 [16935849.001]
  • [Cites] Digestion. 2006;74(1):42-6 [17068397.001]
  • [Cites] Gut. 2006 Nov;55(11):1538-44 [16785284.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] Carcinogenesis. 2006 Jul;27(7):1301-9 [16638787.001]
  • [Cites] Br J Cancer. 2006 Jul 3;95(1):118-22 [16755290.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):288-93 [16492917.001]
  • (PMID = 21180511.001).
  • [ISSN] 1756-283X
  • [Journal-full-title] Therapeutic advances in gastroenterology
  • [ISO-abbreviation] Therap Adv Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3002491
  • [Keywords] NOTNLM ; adenocarcinoma / chemoprevention / esophageal cancer
  •  go-up   go-down


30. Fraguela Mariña JA, Fernández Blanco C, Alonso Fernández L, Taboada Filgueira L, Robles Veiga O, Gómez Freijoso C: [Liver metastases from colonic adenocarcinoma simulating cholangiocarcinoma]. Gastroenterol Hepatol; 2007 Oct;30(8):454-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver metastases from colonic adenocarcinoma simulating cholangiocarcinoma].
  • [Transliterated title] Metástasis hepática de cáncer de recto simulando un colangiocarcinoma.
  • Macroscopic intrabiliary growth of liver metastases from colonic adenocarcinoma mimicking cholangiocarcinoma, a pattern of intrahepatic spread easily confused with primary neoplasia of the biliary tract, is extremely infrequent.
  • Resection of liver metastases has a better prognosis than that of primary neoplasia of the biliary tract.
  • We report a case of metastasis from adenocarcinoma of the colon that presented as a Klatskin tumor.
  • The definitive diagnosis was established by immunostaining.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Bile Duct Neoplasms / diagnosis. Cholangiocarcinoma / diagnosis. Colonic Neoplasms / pathology. Klatskin Tumor / diagnosis. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17949611.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


31. Tanaka H, Sato H, Konishi Y, Fujimoto T, Takahashi O, Tanaka T: Endometrial adenocarcinoma after liver transplantation. J Obstet Gynaecol Res; 2005 Jun;31(3):224-6
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma after liver transplantation.
  • In June 1999, a 50-year-old Japanese woman underwent a liver transplant and was started on tacrolimus hydrate.
  • In December 2001, the patient was found to suffer from endometrial adenocarcinoma and total abdominal hysterectomy with adnexa was carried out.
  • No significant changes in liver function were observed.
  • The present case is the first report of endometrial adenocarcinoma in a patient after liver transplantation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Liver Transplantation
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15916658.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Kim HR, Cheon SH, Lee KH, Ahn JR, Jeung HC, Lee SS, Chung HC, Noh SH, Rha SY: Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. Int J Hyperthermia; 2010;26(4):305-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma.
  • PURPOSE: Optimal treatment for liver metastases from gastric cancer remains a matter of debate.
  • The aim of our study is to evaluate the efficacy of radiofrequency ablation (RFA) for the treatment of liver-only metastases from gastric adenocarcinoma.
  • MATERIALS AND METHODS: We retrospectively reviewed medical records of 29 patients who developed liver-only metastases from gastric adenocarcinoma and subsequently underwent gastric resection and RFA (n = 20) or gastric resection and systemic chemotherapy (n = 9) between January 1995 and February 2008.
  • One case of treatment-related death occurred due to sepsis that originated from a liver abscess at the ablation site.
  • CONCLUSIONS: The data suggest that a use of RFA as a liver-directed treatment may provide greater survival benefit than chemotherapy and is an alternative option for the treatment of liver-only metastases from gastric cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Feasibility Studies. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20210605.001).
  • [ISSN] 1464-5157
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


33. Moreno-Vega AL, Fuentes-Pradera J, Gordón-Santiago Mdel M, Vargas-Machuca JC: Intraventricular metastases from rectal-sigmoid adenocarcinoma. Clin Transl Oncol; 2006 Apr;8(4):296-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraventricular metastases from rectal-sigmoid adenocarcinoma.
  • Adenocarcinoma accounted for around 40% of all metastases to the heart; the most frequently involved sites are pericardium and epicardium.
  • We present a patient with an unusual intraventricular metastases from adenocarcinoma of rectal-sigmoid origin.
  • [MeSH-major] Adenocarcinoma / secondary. Heart Neoplasms / secondary. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Capecitabine. Cardiac Tamponade / etiology. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dyspnea / etiology. Fatal Outcome. Female. Fluorouracil / analogs & derivatives. Heart Ventricles / radiography. Heart Ventricles / ultrasonography. Humans. Liver Neoplasms / secondary. Organoplatinum Compounds / administration & dosage. Palliative Care

  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648108.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


34. Zhanaeva SY, Korolenko TA, Nekrasov BG, Nikolin VP, Kaledin VI: Stimulation of macrophages increases, while suppression of these cells inhibits metastatic dissemination of two transplantable mouse tumors in the liver and lungs. Bull Exp Biol Med; 2005 Oct;140(4):449-51
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stimulation of macrophages increases, while suppression of these cells inhibits metastatic dissemination of two transplantable mouse tumors in the liver and lungs.
  • Stimulation of mouse tissue macrophages with carboxymethylated beta-(1-->43)-D-glycan 1 day before intravenous injection of tumor cells increased the number and weight of implants (experimental metastases) of mouse hepatocarcinoma and adenocarcinoma in the liver and lungs, respectively.
  • Suppression of liver macrophages with gadolinium chloride or sequestration of cells during intraperitoneal administration of macrophage attractants inhibited metastatic dissemination of hepatocarcinoma and adenocarcinoma in the liver and lungs, respectively.
  • [MeSH-major] Adenocarcinoma / secretion. Carcinoma, Hepatocellular / secretion. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Macrophages / immunology
  • [MeSH-minor] Animals. Gadolinium / pharmacology. Male. Mice. Mice, Inbred Strains. Neoplasm Transplantation. Polysaccharides / pharmacology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16671578.001).
  • [ISSN] 0007-4888
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Polysaccharides; AU0V1LM3JT / Gadolinium; P7082WY76D / gadolinium chloride
  •  go-up   go-down


35. Pereira ME, Viner TC: Oviduct adenocarcinoma in some species of captive snakes. Vet Pathol; 2008 Sep;45(5):693-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oviduct adenocarcinoma in some species of captive snakes.
  • This article reports 5 cases of oviduct adenocarcinoma in adult captive snakes from Smithsonian's National Zoological Park.
  • This neoplasm was found in 1 of each of the following species: emerald tree boa (Corallus caninus), Amazonian tree boa (Corallus enydris enydris), Burmese rock python (Python molurus bivittatus), Northern pine snake (Pituophis melanoleucus melanoleucus), and corn snake (Elaphe guttata).
  • Solid metastases were seen in all animals except the Northern pine snake and involved several organs including the liver, lung, and heart.
  • [MeSH-major] Adenocarcinoma / veterinary. Animals, Zoo. Genital Neoplasms, Female / veterinary. Oviducts / pathology. Snakes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18725476.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Ciurea S, Matei E, Petrisor P, Luca L, Boros M, Herlea V, Popescu I: Gallbladder adenoma with focal adenocarcinoma. Chirurgia (Bucur); 2008 May-Jun;103(3):355-8
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallbladder adenoma with focal adenocarcinoma.
  • The case of a 52-year old male patient with an adenomatous polyp of the GB with focal adenocarcinoma is presented.
  • [MeSH-major] Adenocarcinoma. Adenoma. Gallbladder Neoplasms. Neoplasms, Multiple Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18717288.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


37. Nair PS, Moorthy PK, Suprakasan S, Jayapalan S, Sarin M: Malignant acanthosis nigricans with liver secondaries from an occult primary adenocarcinoma of gastrointestinal tract. Indian J Dermatol Venereol Leprol; 2005 May-Jun;71(3):197-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant acanthosis nigricans with liver secondaries from an occult primary adenocarcinoma of gastrointestinal tract.
  • Investigations revealed multiple secondaries in the liver.
  • Histopathology showed the secondaries to be from adenocarcinoma of the gastrointestinal tract.
  • [MeSH-major] Acanthosis Nigricans / pathology. Adenocarcinoma / secondary. Liver Neoplasms / secondary. Paraneoplastic Syndromes / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Acanthosis Nigricans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16394413.001).
  • [ISSN] 0378-6323
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


38. Rizell M, Lindner P: Inhibition of mTOR suppresses experimental liver tumours. Anticancer Res; 2005 Mar-Apr;25(2A):789-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of mTOR suppresses experimental liver tumours.
  • Sirolimus, and its antiproliferative capacity, was studied in vivo in three different syngenic rat tumours in the liver.
  • Treating established liver adenocarcinoma (n=15), sirolimus halved the tumour weight (1.4+/-0.2 g vs 0.7+/-0.1 g, p=0.005).
  • At this dose, there was no decrease in food consumption or rat weight, but decrease in weight of spleen, and increase in weight of liver (p<0.01).
  • The three tumours studied, an nitrosoguanidin-induced adenocarcinoma, a Leydig cell sarcoma and a hepatoma, all responded, establishing sirolimus as a promising anticancer drug.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Liver Neoplasms, Experimental / drug therapy. Liver Neoplasms, Experimental / enzymology. Protein Kinase Inhibitors / pharmacology. Protein Kinases / metabolism. Sirolimus / pharmacology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / enzymology. Animals. Colonic Neoplasms / drug therapy. Colonic Neoplasms / enzymology. Dose-Response Relationship, Drug. Eating / drug effects. Leydig Cell Tumor / drug therapy. Leydig Cell Tumor / enzymology. Liver / anatomy & histology. Liver / metabolism. Organ Size / drug effects. Rats. Rats, Inbred WF. Spleen / anatomy & histology. TOR Serine-Threonine Kinases

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868910.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Protein Kinase Inhibitors; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, rat; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


39. Safaee A, Moghimi-Dehkordi B, Fatemi SR, Ghiasi S, Nemati-Malek F, Zali MR: Characteristics of colorectal mucinous adenocarcinoma in Iran. Asian Pac J Cancer Prev; 2010;11(5):1373-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of colorectal mucinous adenocarcinoma in Iran.
  • AIMS AND BACKGROUND: Mucinous adenocarcinoma (MA) colorectal cancer accounts for 10 to 15% of colorectal carcinoma.
  • RESULTS: The median age of these patients at diagnosis was 50.07 years.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Iran / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21198295.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


40. Shinji S, Naito Z, Ishiwata T, Tanaka N, Furukawa K, Suzuki H, Seya T, Kan H, Tsuruta H, Matsumoto S, Matsuda A, Teranishi N, Ohaki Y, Tajiri T: Neuroendocrine cell differentiation of poorly differentiated colorectal adenocarcinoma correlates with liver metastasis. Int J Oncol; 2006 Aug;29(2):357-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine cell differentiation of poorly differentiated colorectal adenocarcinoma correlates with liver metastasis.
  • Poorly differentiated (PD) adenocarcinoma often retains the capacity for neuroendocrine (NE) cell differ-entiation; however, it is difficult to distinguish the NE cell differentiation by routine hematoxylin and eosin staining.
  • It is important to detect the presence of NE cell differentiation in advanced colorectal carcinomas because these carcinomas have been shown to produce distant metastasis at the time of diagnosis and to have a particularly poor prognosis.
  • In this study, the characteristics of PD adenocarcinoma with NE cell differentiation and its biological metastatic mechanisms were investigated.
  • Forty-eight of 2204 colorectal cancer patients, diagnosed as having PD adenocarcinoma (2.2%) were enrolled in this study.
  • The clinicopathological factors for PD adenocarcinoma with NE cell differentiation were compared with those for PD adenocarcinoma without NE cell differentiation.
  • Microvessel density (MVD) was assessed using immunostained slides with anti-CD34 antibody and vascular endothelial growth factor (VEGF) expression in PD adenocarcinoma with NE cell differentiation was confirmed by in situ hybridization.
  • By immunohistochemical staining for chromogranin A and synaptophysin, NE cell differentiation was detected in eight of 48 patients (16.7%) with PD adenocarcinoma.
  • The frequency of liver metastasis at the time of diagnosis was significantly higher in patients having PD adenocarcinoma with NE cell differentiation (p=0.03).
  • Moreover, MVD and VEGF expression level tended to be higher in patients having PD adenocarcinoma with NE cell differentiation (p=0.13 and 0.068, respectively).
  • NE cell differentiation in PD adenocarcinoma may produce liver metastasis through microvessel formation in the tumor induced by VEGF.
  • In PD colorectal adenocarcinoma, immunohistochemical analysis of NE markers is important for establishing the presence of NE cell differentiation and further study is necessary to evaluate the effectiveness of anti-angiogenic drugs to PD adenocarcinoma with NE cell differentiation.
  • [MeSH-major] Adenocarcinoma / metabolism. Antibodies, Monoclonal / chemistry. Carcinoma, Neuroendocrine / pathology. Colorectal Neoplasms / metabolism. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD34 / biosynthesis. Cell Differentiation. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820877.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD34; 0 / monoclonal antibody D2-40
  •  go-up   go-down


41. Zaanan A, Lequoy M, Landi B, Lievre A, Franco D, Taïeb J: Brain metastases from pancreatic adenocarcinoma. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases from pancreatic adenocarcinoma.
  • Brain metastases from pancreatic adenocarcinoma (PA) are extremely rare.
  • We report the case of a patient with PA treated by chemotherapy for liver and lung metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2001 Mar;37(3):227-36 [11248578.001]
  • [Cites] J Neuroimmunol. 1998 Aug 14;89(1-2):104-12 [9726832.001]
  • [Cites] Pancreatology. 2006;6(4):306-8 [16636605.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Jul;30(7):476-82 [1701858.001]
  • [Cites] Gastroenterol Clin Biol. 2007 Feb;31(2):233-9 [17347640.001]
  • [Cites] Biochem Biophys Res Commun. 1996 May 24;222(3):794-801 [8651925.001]
  • [Cites] Surg Neurol. 2002 Nov;58(5):332-6; discussion 336-7 [12504302.001]
  • [Cites] Virchows Arch. 1996 Nov;429(4-5):191-5 [8972753.001]
  • [Cites] J Neurooncol. 2003 Jul;63(3):313-6 [12892239.001]
  • [Cites] Dig Liver Dis. 2004 May;36(5):355-60 [15191206.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3509-16 [15908661.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):498-503 [17158774.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1663-74 [17363519.001]
  • [Cites] J Mol Med (Berl). 1996 May;74(5):253-68 [8773262.001]
  • [Cites] Gastroenterol Clin Biol. 2006 Jan;30(1):106-9 [16514388.001]
  • (PMID = 21686720.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028083
  •  go-up   go-down


42. Hornick JL, Lauwers GY, Odze RD: Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol; 2005 Mar;29(3):381-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver.
  • Not uncommonly, bile duct adenomas (BDAs) and hamartomas (BDHs) of the liver may be difficult to distinguish from metastatic well-differentiated ductal adenocarcinoma of the pancreas.
  • The primary purpose of this study was to determine if a panel of immunohistochemical stains can help distinguish BDA or BDH from metastatic pancreatic adenocarcinoma in the liver.
  • Routinely processed tissue sections from 25 BDA, 10 BDH, 25 metastatic pancreatic adenocarcinomas to the liver and 6 cases each of metastatic colorectal, breast, and lung adenocarcinomas were immunohistochemically stained for CK7, CK8/CK18, CK19, CK20, p53, p63, TAG-72, monoclonal CEA (mCEA), polyclonal CEA (pCEA), HER-2/neu, AMACR (alpha-methylacyl-CoA racemase), Dpc4 (Smad4), and mesothelin.
  • The slides were evaluated in a blinded fashion, and the results were compared between the benign and malignant lesions.
  • Of these antibodies, p53, TAG-72, mCEA, loss of Dpc4, and mesothelin had the highest specificity for pancreatic adenocarcinoma, with mCEA having the highest sensitivity (92%).
  • For nonpancreatic adenocarcinomas, mCEA showed a reasonably high sensitivity and 100% specificity in the differential diagnosis versus BDA.
  • Immunohistochemical expression of p53, TAG-72, mCEA, mesothelin, and loss of Dpc4 can help distinguish metastatic pancreatic adenocarcinoma in the liver from BDA or BDH.
  • Although p63 and AMACR are also specific for pancreatic adenocarcinoma, their low sensitivity limits their use in clinical practice.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma / pathology. Bile Duct Neoplasms / pathology. Hamartoma / pathology. Liver Diseases / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Immunoenzyme Techniques


43. Vrettou E, Hytiroglou P, Sikas N, Soultoyannis I, Goodman ZD: Hepatic adenocarcinoma expressing inhibin in a young patient on oral contraceptives. Virchows Arch; 2005 May;446(5):560-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic adenocarcinoma expressing inhibin in a young patient on oral contraceptives.
  • A case of primary hepatic carcinoma is reported, which occurred in a 24-year-old woman with a 10-year history of oral contraceptive use, and demonstrated unique morphologic and immunohistochemical features.
  • The tumor was located in the left hepatic lobe, measured 14 cm at its widest, and showed histologic heterogeneity.
  • Interestingly, they were positive for inhibin, a protein that is known to be expressed in sex cord-stromal tumors of the ovary, trophoblastic neoplasms and adrenal cortical tumors, but not in hepatic tumors.
  • [MeSH-major] Adenocarcinoma / diagnosis. Contraceptives, Oral, Combined / administration & dosage. Inhibins / analysis. Liver Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15815932.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Contraceptives, Oral, Combined; 0 / KRT7 protein, human; 0 / Keratin-7; 57285-09-3 / Inhibins; 68238-35-7 / Keratins
  •  go-up   go-down


44. Tazi N, Le Thi Huong D, Bodaghi B, Rixe O, Lehoang P, Piette JC: [Choroidal metastasis revealing pulmonary adenocarcinoma]. Rev Med Interne; 2006 Sep;27(9):699-701
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choroidal metastasis revealing pulmonary adenocarcinoma].
  • He presented with visual decrease and metamorphopsia that lead to the diagnosis of a metastatic adenocarcinoma of the lung (bone, liver, choroid, nodles).

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16872723.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


45. Zheng H, Tsuneyama K, Cheng C, Takahashi H, Cui Z, Murai Y, Nomoto K, Takano Y: Maspin expression was involved in colorectal adenoma-adenocarcinoma sequence and liver metastasis of tumors. Anticancer Res; 2007 Jan-Feb;27(1A):259-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin expression was involved in colorectal adenoma-adenocarcinoma sequence and liver metastasis of tumors.
  • This study aimed to explore the roles of maspin expression in the tumorigenesis and progression of colorectal adenocarcinoma (CRA).
  • RESULTS: Maspin expression showed significant increase from colorectal non-cancerous mucosa to adenocarcinoma through adenoma (p < 0.05).
  • Maspin expression correlated negatively with liver metastasis of CRA (p < 0.05), positively with tenascin expression (p < 0.05), but not with tumor size, depth of invasion, local invasion via vessels, lymph node metastasis, differentiation, expression of Ki-67 and p53 or MVD (p > 0.05).
  • CONCLUSION: Up-regulated maspin expression was involved in colorectal adenoma-adenocarcinoma sequence.
  • Low maspin expression is closely linked to the liver metastasis of CRA possibly through degradation of the extracellular matrix-tenascin to enhance carcinoma cell mobility.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / metabolism. Colorectal Neoplasms / metabolism. Liver Neoplasms / secondary. Serpins / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352241.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / SERPIN-B5; 0 / Serpins; 0 / Tenascin
  •  go-up   go-down


46. Zheng H, Tsuneyama K, Cheng C, Takahashi H, Cui Z, Nomoto K, Murai Y, Takano Y: Expression of KAI1 and tenascin, and microvessel density are closely correlated with liver metastasis of gastrointestinal adenocarcinoma. J Clin Pathol; 2007 Jan;60(1):50-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of KAI1 and tenascin, and microvessel density are closely correlated with liver metastasis of gastrointestinal adenocarcinoma.
  • AIM: To seek good markers to predict invasion and metastasis of gastrointestinal adenocarcinoma (GIA).
  • METHODS: Expression of KAI1 and tenascin were examined on tissue microarrays containing gastric adenocarcinoma (n = 98), colorectal adenocarcinoma (n = 125), gastric adjacent non-cancerous mucosa (n = 95) and colorectal adjacent non-cancerous mucosa (n = 112) by immunostaining.
  • KAI1 and tenascin expression showed a significantly negative association with liver metastasis of GIA (p<0.05), but not with depth of invasion, venous invasion or lymph node metastasis (p>0.05).
  • MVD was positively correlated with depth of invasion, venous invasion, lymph node metastasis and liver metastasis of tumours (p<0.05), whereas it was negatively correlated with PTEN expression (p<0.05).
  • CONCLUSIONS: Up-regulated KAI1 expression may play an important part in malignant transformation of gastrointestinal epithelial cells.
  • Reduced expression of KAI1 and tenascin might underlie the molecular basis of liver metastasis of GIA.
  • These markers might be used to indicate liver metastasis of GIA in clinicopathological practice.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Biomarkers, Tumor / metabolism. Liver Neoplasms / secondary. Neoplasm Proteins / metabolism. Neovascularization, Pathologic / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD82 / metabolism. Colorectal Neoplasms / blood supply. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Female. Humans. Lymphatic Metastasis. Male. Microcirculation / pathology. Middle Aged. Neoplasm Invasiveness. Stomach Neoplasms / blood supply. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Tenascin / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2001 Dec 24;155(7):1103-7 [11756464.001]
  • [Cites] Genes Cells. 2001 Dec;6(12):1101-11 [11737270.001]
  • [Cites] Res Vet Sci. 2002 Aug;73(1):1-8 [12208101.001]
  • [Cites] Ann Neurol. 2003 Jan;53(1):109-17 [12509854.001]
  • [Cites] Oncology. 2003;64(3):245-50 [12697965.001]
  • [Cites] Pathol Int. 2003 Oct;53(10):659-66 [14516315.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):31-40 [14618612.001]
  • [Cites] FASEB J. 2004 Jan;18(1):158-60 [14597553.001]
  • [Cites] Mol Cancer Res. 2004 Feb;2(2):73-80 [14985463.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4235-43 [15205336.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1141-9 [15167936.001]
  • [Cites] Arthritis Rheum. 2004 Sep;50(9):2742-9 [15457441.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):169-80 [8534865.001]
  • [Cites] Jpn J Cancer Res. 1998 Apr;89(4):397-404 [9617345.001]
  • [Cites] Clin Cancer Res. 1995 Sep;1(9):1035-41 [9816077.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):415-21 [10366470.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 17;96(22):1645-7 [15547171.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Mar;37(3):530-4 [15618009.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6 Suppl 17):3-9 [15696024.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):361-8 [15781323.001]
  • [Cites] Br J Plast Surg. 2005 Jun;58(4):466-74 [15897029.001]
  • [Cites] Surgery. 1999 Nov;126(5):869-80 [10568187.001]
  • [Cites] Histochem J. 2001 Feb;33(2):111-20 [11432639.001]
  • [Cites] Prog Brain Res. 2001;132:103-14 [11544980.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1629-34 [11696423.001]
  • [Cites] Ann Surg Oncol. 2002 Aug;9(7):610-6 [12167573.001]
  • (PMID = 16698949.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD82; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Tenascin
  • [Other-IDs] NLM/ PMC1860584
  •  go-up   go-down


47. Miller FH, Rini NJ, Keppke AL: MRI of adenocarcinoma of the pancreas. AJR Am J Roentgenol; 2006 Oct;187(4):W365-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI of adenocarcinoma of the pancreas.
  • OBJECTIVE: CT is the established imaging technique for evaluation of pancreatic adenocarcinoma.
  • The objective of this study is to illustrate the strengths of MRI for evaluating pancreatic adenocarcinoma.
  • MRI compared with CT may be more sensitive in the detection of distant disease, better for defining appropriate surgical candidates, and better for characterizing small liver metastases and peritoneal and omental metastases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Magnetic Resonance Imaging. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / radiography. Diagnosis, Differential. Humans. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Pancreatitis / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16985107.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Hong K, McBride JD, Georgiades CS, Reyes DK, Herman JM, Kamel IR, Geschwind JF: Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol; 2009 Mar;20(3):360-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization.
  • PURPOSE: To compare transarterial chemoembolization (CE) versus yttrium-90 ((90)Y) radioembolization (RE) for liver-dominant metastatic colorectal adenocarcinoma as salvage therapy.
  • MATERIALS AND METHODS: Of 36 patients, 21 underwent CE (37 procedures; 11 men; mean age, 67 years; 16 with Child-Pugh class A disease) and 15 underwent (90)Y RE (19 procedures; 11 men; mean age, 64 years; 13 with Child-Pugh class A disease) for liver-dominant colorectal adenocarcinoma.
  • Mean times from diagnosis of liver metastasis to CE or RE were 17.6 months and 22.6 months, respectively.
  • CONCLUSIONS: Patients with unresectable liver colorectal metastases that progress despite systemic chemotherapy can undergo palliative treatment with CE or RE with similar survival benefit.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Chemoembolization, Therapeutic / methods. Colorectal Neoplasms / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Yttrium Radioisotopes / therapeutic use

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19167245.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0 / Yttrium Radioisotopes
  •  go-up   go-down


49. Kilian M, Gregor JI, Heukamp I, Helmecke K, Hanel M, Wassersleben B, Walz MK, Schimke I, Kristiansen G, Wenger FA: Impact of Octreotide and SOM-230 on liver metastasis and hepatic lipidperoxidation in ductal pancreatic adenocarcinoma in Syrian Hamster. Clin Exp Metastasis; 2009;26(7):719-27
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of Octreotide and SOM-230 on liver metastasis and hepatic lipidperoxidation in ductal pancreatic adenocarcinoma in Syrian Hamster.
  • In previous trials Octreotide showed inhibitory effects on tumour growth and liver metastasis in experimental pancreatic cancer.
  • Pancreas and liver were histopathologically analysed.
  • Hepatic lipidperoxidation was determined by activities of antioxidative enzymes gluthation-peroxidase (GSH-Px) and superoxiddismutase (SOD) as well as concentration of thiobarbituric-acid reactive substances (TBARS).
  • Incidence of liver metastases was 88.2% in Gr.2 (BOP/Aqua), it was decreased in Gr.4 (BOP/Octreo: 40%) and Gr.6 (BOP/SOM-230: 50%) (P < 0.05).
  • Mean number/animal and mean-2-dimensional size of liver metastases did not differ between tumour groups.
  • Comparing GSH-Px-activity in intrametastatic and extrametastatic hepatic tissue revealed a significant increase extrametastatically in Gr.2 (BOP/Aqua) and Gr.6 (BOP/SOM-230).
  • SOD-activity in liver metastases was decreased in Gr.2 (1,801) (P < 0.05) versus Gr.4 (8,304) and Gr.6 (7,038).
  • Octreotide and SOM-230 equally reduced liver metastasis in ductal pancreatic adenocarcinoma probably by a reduction of lipidperoxidation.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Lipid Peroxidation. Liver / drug effects. Octreotide / pharmacology. Pancreatic Neoplasms / pathology. Somatostatin / analogs & derivatives

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19521786.001).
  • [ISSN] 1573-7276
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Thiobarbituric Acid Reactive Substances; 51110-01-1 / Somatostatin; 98H1T17066 / pasireotide; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase; RWM8CCW8GP / Octreotide
  •  go-up   go-down


50. Kato K, Suzuka K, Osaki T, Itami M, Tanaka N: Primary hepatoid adenocarcinoma of the uterine cervix. Int J Gynecol Cancer; 2007 Sep-Oct;17(5):1150-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatoid adenocarcinoma of the uterine cervix.
  • Hepatoid adenocarcinoma is characterized histologically by neoplastic epithelial cells that resemble hepatocellular carcinoma (HCC) and produce alpha-fetoprotein (AFP).
  • We describe a case of hepatoid adenocarcinoma of the uterus that, unlike any other previously reported case, was strictly confined to the cervix.
  • A cervical biopsy demonstrated poorly differentiated adenocarcinoma, and hysterectomy and bilateral salpingo-oophorectomy were subsequently performed.
  • Histologically, the lesion consisted of solid sheets of hepatoid cells accompanied with areas of endometroid adenocarcinoma.
  • The tumor cells showed strong and diffuse cytoplasmic immunoreactivity with AFP in both medullary and adenocarcinoma components.
  • To our knowledge, this is the first report of primary hepatoid adenocarcinoma of the uterine cervix.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367323.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 15
  •  go-up   go-down


51. Murad JC, Ribeiro U Jr, Safatle-Ribeiro AV, Parra E, Rawet V, Corbett CE, Ferreira VA, Pugliese V, Saad WA, Habr-Gama A, Gama-Rodrigues J: Evaluation of molecular markers in hepatic metastasis of colorectal adenocarcinoma. Hepatogastroenterology; 2007 Jun;54(76):1029-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of molecular markers in hepatic metastasis of colorectal adenocarcinoma.
  • BACKGROUND/AIMS: There were 49 patients studied, coming from The Liver Unit at the "Hospital das Clinicas da Faculdade de Medicina da USP (N=41) and from "Prof. Dr.
  • Angelita Habr-Gama and Joaquim Gama-Rodrigues Surgery Institute", SP (N=8); all of which had hepatic metastasis of colorectal adenocarcinoma, with no evidence of concurrent metastasis in any other organs and were submitted to surgical treatment, during the period of 1992 to 2002, with the aim of analyzing the immunoexpression of the p53, ki-67, p16 and molecular markers in order to relate the disease-free period with the prognosis.
  • METHODOLOGY: The patient's clinical data were analyzed retrospectively for verification of information such as age, gender, size of the hepatic metastasis and/or the largest lesion, number of satellite nodules resected and compromised, margin of resection free from neoplasia.
  • The proliferation marker ki-67 was not associated with the reduction of the disease-free interval and survival; the immunoexpression of the proliferation marker p16 was not associated with the reduction of disease-free period and survival, however, it was associated with hepatic metastasis synchronism.
  • In patients who received postoperative systemic chemotherapy with 5-FU and leucovorin, the immunoexpression on the hepatic metastasis was not associated with a longer disease-free interval.
  • CONCLUSIONS: Molcular markers may be useful to evaluate hepatic metastasis of colorectal Adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Colorectal Neoplasms / pathology. Liver Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629032.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


52. Jeong EH, Kim DH, Ma SH, Chung EJ, Bae SS, Park AY, Chu HJ: [A case of liver metastasis of gastric hepatoid adenocarcinoma]. Korean J Hepatol; 2009 Jun;15(2):201-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of liver metastasis of gastric hepatoid adenocarcinoma].
  • We report herein a case of hepatoid adenocarcinoma of the stomach with liver metastasis.
  • Gastric carcinoma generally presents as adenocarcinoma and rarely shows a hepatoid pattern, which can produce alpha-fetoprotein (AFP).
  • The stomach is one of the common sites at which hepatoid adenocarcinoma has been detected.
  • Abdominal computed tomography revealed multiple liver masses.
  • Biopsy samples of the gastric lesion and liver masses finally confirmed her case as hepatoid adenocarcinoma in the stomach with liver metastasis.
  • The AFP-producing gastric carcinoma needs special attention because it often presents with early liver metastasis and has a poor prognosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Liver Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581772.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


53. Gleisner AL, Assumpcao L, Cameron JL, Wolfgang CL, Choti MA, Herman JM, Schulick RD, Pawlik TM: Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer; 2007 Dec 1;110(11):2484-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?
  • BACKGROUND: To date, no consensus has been reached regarding which primary tumor subtypes are managed appropriately with hepatic metastectomy.
  • Specifically, the role of hepatic resection for metastatic periampullary or pancreatic adenocarcinoma remains controversial.
  • METHODS: Between 1995 and 2005, 1563 patients underwent surgical resection for periampullary carcinoma (n=608 patients) or pancreatic adenocarcinoma (head, n=905 patients; tail, n=50 patients).
  • Data on demographics, operative details, primary tumor status, and-when indicated-extent of hepatic metastasis were collected.
  • RESULTS: Of the 1563 patients who underwent resection of periampullary or pancreatic adenocarcinoma, 22 patients (1.4%) underwent simultaneous hepatic resection for synchronous liver metastasis.
  • The majority of patients (86.4%) had a solitary hepatic metastasis, and the median size of the largest lesion was 0.6 cm.
  • Hepatic metastectomy included wedge resection (n=20 patients), segmentectomy (n=1 patient), and hemihepatectomy (n=1 patient).
  • After matching patients on primary tumor histology and location, the median survival of patients who underwent hepatic resection of synchronous metastasis was 5.9 months compared with 5.6 months for patients who underwent palliative bypass alone (P=.46) and 14.2 months for patients with no metastatic disease who underwent primary tumor resection only (P<.001).
  • Pancreatic (median, 5.9 months) versus nonpancreatic (median, 9.9 months) primary tumor histology was not associated with a difference in survival in patients who underwent resection of synchronous liver metastasis (P=.43).
  • CONCLUSIONS: Even in well selected patients with low-volume metastatic liver disease, simultaneous resection of periampullary or pancreatic carcinoma with synchronous liver metastases did not result in long-term survival in the overwhelming majority of patients.
  • [MeSH-major] Adenocarcinoma / surgery. Liver Neoplasms / secondary. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 American Cancer Society.
  • (PMID = 17941009.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Maksimović S: [Survival rates of patients with mucinous adenocarcinoma of the colorectum]. Med Arh; 2007;61(1):26-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival rates of patients with mucinous adenocarcinoma of the colorectum].
  • PURPOSE: Mucinous adenocarcinoma is one of the histological subtypes of colorectal cancer.
  • Frequently are more advanced at diagnosis and have a poorer prognosis than nonmucinous colorectal adenocarcinomas.
  • To determine whether the mucinous adenocarcinoma itself was independent prognostic factor in the curative resected patients, a multivariate analysis was performed.
  • RESULTS: The mucinous adenocarcinoma patients compared to patients with nonmucinous adenocarcinoma patients were found to be younger (p= 0,001), have more lymph node metastases (46,15% vs. 38,31%, p=0,0053), more peritoneal dissemination (20,51% vs. 5,1%, p <0,0001), greater frequency of advanced stage disease (p= 0,0006), lower rate of curative resection (76,3% vs. 84,9%, p=0,0045), and lower overall 5-year survival rates (39% vs. 60,3%, p=0,0002.
  • Although the weight of the published literature suggests that mucinous adenocarcinoma is associated with poorer outcome, contradictory reports suggest that the clinical relevance of this histological type in this patient population remains unclear The lack of consensus may be attributable to the limited detection power inherent in studies that test small subsets of patients and the diversity inherent in the inclusion of patients with all Dukes' stages in the analysis.
  • Indeed, these series studied prognosis from initial diagnosis, generally in patients treated with surgery alone, and did not specifically address outcomes in patients treated with chemotherapy.
  • Mucinous tumors were associated with a higher proportion of patients with nodal metastases and peritoneal metastases, while the most common site of metastases for patients with non-mucinous histology was the liver.
  • [MeSH-major] Adenocarcinoma, Mucinous / mortality. Colorectal Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582971.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] bos
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Bosnia and Herzegovina
  • [Number-of-references] 25
  •  go-up   go-down


55. Germanos S, Gourgiotis S, Stavrothanasopoulou A, Alepas P, Zampitis N, Panteli A: Diagnostic and therapeutic approach to pancreatic adenocarcinoma. J Gastrointestin Liver Dis; 2006 Sep;15(3):257-63
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and therapeutic approach to pancreatic adenocarcinoma.
  • Pancreatic adenocarcinoma is the sixth leading cause of cancer-related death in Europe with survival rates remaining unchanged over the last three decades.
  • Early diagnosis and accurate staging are essential due to the difficulty of curing this tumor in its advanced form.
  • Endoscopic or laparoscopic ultrasonography and computed tomography are the preferred imaging and staging modalities for many patients with pancreatic adenocarcinoma.
  • This article reviews the causes, risk factors, and clinical features of pancreatic adeno-carcinoma and discusses the methods of optimal diagnosis, staging and treatment.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17013451.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 71
  •  go-up   go-down


56. Zhu MH, Hu XG, Ni CR, Zhang SM, Xi PC, Yu GZ: [Mucinous noncystic (colloid) adenocarcinoma of the pancreas]. Zhonghua Bing Li Xue Za Zhi; 2005 Jul;34(7):389-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mucinous noncystic (colloid) adenocarcinoma of the pancreas].
  • OBJECTIVE: To determine the clinicopathologic characteristics and the relationship between related gene expression and pathobiologic behavior of pancreatic mucinous noncystic adenocarcinoma.
  • Tumor metastasis in the liver was seen in 2 cases and in the regional lymph nodes in 2 cases.
  • CONCLUSIONS: Pancreatic mucinous noncystic adenocarcinoma has distinct morphologic features and biologic behavior.
  • The tumor has an aggressive behavior with a high frequency of invasion and metastases, though the prognosis could be better than that of ordinary ductal adenocarcinoma of pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Duodenal Neoplasms / pathology. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Proto-Oncogene Proteins p21(ras) / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16251039.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


57. Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D, Emme D, Röder C, Kalthoff H, Wajant H: TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene; 2006 Nov 30;25(56):7434-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma.
  • Here, we show that TRAIL strongly induces the expression of the proinflammatory cytokines interleukin-8 and monocyte chemoattractant protein 1 and enhances the invasion of apoptosis-resistant pancreatic ductal adenocarcinoma cells in vitro by upregulation of the urokinase-type plasminogen activator expression.
  • We orthotopically transplanted human pancreatic ductal adenocarcinoma cells to the pancreata of severe combined immunodeficiency mice and observed a dramatic increase in metastatic spread including a sixfold increase in the volume and fourfold increase in the number of liver metastases upon TRAIL treatment.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Neoplasm Metastasis. Pancreatic Neoplasms / pathology. TNF-Related Apoptosis-Inducing Ligand / physiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16751802.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human
  •  go-up   go-down


58. Tantau M, Mosteanu O, Pop T, Tantau A, Mester G: Endoscopic therapy of Barrett's esophagus and esophageal adenocarcinoma. J Gastrointestin Liver Dis; 2010 Jun;19(2):213-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic therapy of Barrett's esophagus and esophageal adenocarcinoma.
  • The rise of esophageal adenocarcinoma (EAC) incidence surpasses any other cancer, including melanoma, lymphoma and small cell lung cancer.
  • The correction of the malignant esophageal obstruction improves the symptomatology and life quality, but not survival.
  • [MeSH-major] Adenocarcinoma / therapy. Barrett Esophagus / therapy. Esophageal Neoplasms / therapy. Esophagoscopy

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593060.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Romania
  •  go-up   go-down


59. Stilwell G, Peleteiro MC: Uterine adenocarcinoma with pulmonary, liver and mesentery metastasis in a holstein cow. Vet Med Int; 2010;2010:727856

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine adenocarcinoma with pulmonary, liver and mesentery metastasis in a holstein cow.
  • The clinical and pathology features of a cow with uterine adenocarcinoma and multiple metastasis are described.
  • Necropsy and histopathology exam revealed a uterine adenocarcinoma with multiple pulmonary, liver and mesentery metastasis.
  • Uterine adenocarcinoma with metastasis should be included in the differential diagnosis of cows showing weight loss and mild respiratory distress and palpation of numerous firm nodules in the mesentery should be suggestive of neoplasias' metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Vet Med Assoc. 1970 Dec 1;157(11):1577-84 [4098649.001]
  • [Cites] J Am Vet Med Assoc. 1966 Apr 15;148(8):913-5 [5950882.001]
  • [Cites] J Comp Pathol. 1969 Jan;79(1):53-63 [5813284.001]
  • (PMID = 20445789.001).
  • [ISSN] 2042-0048
  • [Journal-full-title] Veterinary medicine international
  • [ISO-abbreviation] Vet Med Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2860195
  •  go-up   go-down


60. Alvarez-Alvarez C, Iglesias-Rodríguez B, Pazo-Irazu S, Delgado-Sánchez-Gracián C: Colonic adenocarcinoma with metastasis to the gingiva. Med Oral Patol Oral Cir Bucal; 2006 Jan;11(1):E85-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic adenocarcinoma with metastasis to the gingiva.
  • We report the case of a 62-year-old male who had been diagnosed with sigmoid adenocarcinoma with nodal and liver metastasis, who presented 6 months later with a gingival polypoid tumor, at first considered as a primary neoplasm of gingiva, that was diagnosed in a biopsy as metastatic intestinal adenocarcinoma.
  • The histological evaluation is essential to separate adenocarcinoma from the commoner in this site squamous cell carcinoma, and the immunohistochemical techniques are useful to distinguish metastatic tumor versus primary adenocarcinoma from the minor salivary glands of the area.
  • The intraoral spread of a disseminated neoplasm is generally a sign of bad prognosis, although a longer survival can be expected if a radical surgical treatment of a solitary metastasis is carried out.
  • [MeSH-major] Adenocarcinoma / secondary. Gingival Neoplasms / secondary. Mandibular Neoplasms / secondary. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16388302.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


61. Welsch T, Keleg S, Bergmann F, Bauer S, Hinz U, Schmidt J: Actinin-4 expression in primary and metastasized pancreatic ductal adenocarcinoma. Pancreas; 2009 Nov;38(8):968-76
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinin-4 expression in primary and metastasized pancreatic ductal adenocarcinoma.
  • The present study analyzed the expression of actinin-4 in the pancreas, in localized and metastasized pancreatic ductal adenocarcinoma (PDAC), and the correlation with clinical outcome.
  • METHODS: Pancreatic ductal adenocarcinoma tissue from 38 patients, 15 lymph node and 10 liver metastases, normal pancreas, and 4 PDAC cell lines, were examined by immunohistochemistry, and actinin-4 expression was quantified by immunofluorescence analysis.
  • Cells metastasized to lymph nodes or to the liver exhibited no significant increase of actinin-4 compared with the primary tumors.
  • [MeSH-major] Actinin / metabolism. Carcinoma, Pancreatic Ductal / secondary. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Blotting, Western. Cell Line, Tumor. Humans. Immunohistochemistry. Lymphatic Metastasis. Microscopy, Confocal. Middle Aged. Neoplasm Staging. Pancreas / chemistry. Pancreas / pathology. Survival Analysis. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19672209.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ACTN4 protein, human; 11003-00-2 / Actinin
  •  go-up   go-down


62. Wang Y, Li ZF, He J, Li YL, Zhu GB, Zhang LH, Li YL: Expression of the human phosphatases of regenerating liver (PRLs) in colonic adenocarcinoma and its correlation with lymph node metastasis. Int J Colorectal Dis; 2007 Oct;22(10):1179-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the human phosphatases of regenerating liver (PRLs) in colonic adenocarcinoma and its correlation with lymph node metastasis.
  • BACKGROUND: Human phosphatases of regenerating liver (PRLs) can induce cell growth, differentiation, and malignant transformation.
  • PRLs were mainly expressed in the cytoplasm and at the cytoplasmic membranes of the colonic adenocarcinoma cells as well as in the endothelial cells and the surrounding smooth muscle cells of larger vessels in the lymph node metastases.
  • CONCLUSION: Colonic adenocarcinoma cells have the ability to produce PRLs, which may relate to the lymph node metastasis of colonic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / enzymology. Cell Cycle Proteins / metabolism. Colonic Neoplasms / enzymology. Gene Expression Regulation, Neoplastic. Lymphatic Metastasis / pathology. Membrane Proteins / metabolism. Neoplasm Proteins / metabolism. Protein Tyrosine Phosphatases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440740.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Membrane Proteins; 0 / Neoplasm Proteins; EC 3.1.3.48 / PTP4A1 protein, human; EC 3.1.3.48 / PTP4A2 protein, human; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


63. Ahn SE, Lee HL, Lee OY, Yoon BC, Choi HS, Hahm JS, Park SW, Park HS: [Colonic metastasis from primary lung adenocarcinoma]. Korean J Gastroenterol; 2009 Feb;53(2):121-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colonic metastasis from primary lung adenocarcinoma].
  • The preferential sites of extrapulmonary spread include lymph nodes, liver, brain, adrenal glands, and bones.
  • Herein, we report a case of metastatic colon cancer from primary lung adenocarcinoma, presenting multiple cecal polypoid masses.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Colonic Neoplasms / secondary. Lung Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Radionuclide Imaging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19237839.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


64. Tani M, Kawai M, Miyazawa M, Hirono S, Ina S, Nishioka R, Fujita Y, Uchiyama K, Yamaue H: Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma. Langenbecks Arch Surg; 2009 Mar;394(2):249-53
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma.
  • BACKGROUND: Prognosis of the patients with pancreatic adenocarcinoma is still poor due to a recurrence, and liver metastasis is a distant metastasis that is foreboded the short survival period.
  • METHODS: Between 1999 and 2005, 68 patients for pancreatic adenocarcinoma underwent a pancreaticoduodenectomy (n = 17), a pylorus-preserving pancreaticoduodenectomy (n = 27), distal pancreatectomy (n = 22), or total pancreatectomy (n = 2) with an extensive lymph node dissection.
  • RESULTS: A tumor recurrence occurred to 55 patients (13 of the liver, 21 of the local recurrence, 16 of peritoneal dissemination, three of the lymph node, and two of lung).
  • The low tumor grade and female demonstrated a risk factor for a liver metastasis (P = 0.043, P = 0.031).
  • A logistic regression analysis demonstrated female (P = 0.02) and low tumor grade (P = 0.04) as independent risk factors for recurrence with liver metastasis.
  • The median survival time (MST) was 13.6 months, and MST of patients with a liver metastasis as an initial recurrent site was 13.7 months; the liver metastasis as an initial recurrent site has no impact on the MST after pancreatic resection.
  • CONCLUSIONS: We concluded potentially supporting the hypothesis that even patients thought to be at higher risk of liver metastasis may still be given the chance of resection, considering the satisfying survival.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343944.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


65. Chiu CT, Chiang JM, Yeh TS, Tseng JH, Chen TC, Jan YY, Chen MF: Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma: are they just apples and oranges? Dig Liver Dis; 2008 Sep;40(9):749-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma: are they just apples and oranges?
  • BACKGROUNDS/AIMS: Intrahepatic cholangiocarcinoma and colorectal cancer liver metastasis are the most primary and secondary adenocarcinoma of the liver, respectively.
  • METHODS: A total of 166 colorectal cancer liver metastasis patients and 206 intrahepatic cholangiocarcinoma patients who had undergone curative liver resection were retrospectively analysed.
  • RESULTS: The intrahepatic cholangiocarcinoma patients were more female-predominated, associated with hepatolithiasis, symptomatic, jaundiced, and with larger tumour size compared with those of colorectal cancer liver metastasis.
  • Prognostic factors of intrahepatic cholangiocarcinoma were pathologic staging, histologic pattern and section margin; whereas prognostic factors of colorectal cancer liver metastasis were rectal origin, differentiation, section margin and bilobar distribution.
  • CK7 and CK20 differentiated majority of intrahepatic cholangiocarcinoma from colorectal cancer liver metastasis, while CDX2 and MUC5AC helped to differentiate inconclusive cases.
  • The 1-, 3-, 5- and 10-year survival rates of colorectal cancer liver metastasis were 77%, 31%, 20% and 14%, compared to 53%, 21%, 13% and 7% of intrahepatic cholangiocarcinoma (p=.0001).
  • Furthermore, the survival of colorectal cancer liver metastasis was comparable to staged II intrahepatic cholangiocarcinoma (p=.8866) and intraductal growth type-intrahepatic cholangiocarcinoma (p=.1915).
  • CONCLUSIONS: Demographics, precipitating factor, clinical manifestations, and prognostic factors of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma differed remarkably.
  • High incidence of CDX2 and MUC2 expression in colorectal cancer liver metastasis and intraductal growth type-intrahepatic cholangiocarcinoma might explain their similar cytoarchitecture and survival.
  • [MeSH-major] Adenocarcinoma / secondary. Bile Duct Neoplasms / pathology. Biomarkers, Tumor / analysis. Cholangiocarcinoma / pathology. Colorectal Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Bile Ducts, Intrahepatic. Biopsy, Needle. Cohort Studies. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Probability. Prognosis. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis


66. Varghese S, Burness M, Xu H, Beresnev T, Pingpank J, Alexander HR: Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum. Ann Surg Oncol; 2007 Dec;14(12):3460-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum.
  • Patients with adenocarcinoma of the lower gastrointestinal tract frequently experience diffuse metastases isolated to liver or peritoneum and have a poor survival.
  • METHODS: Microarray analyses of 20 metastatic tumors from patients with colorectal adenocarcinoma isolated to liver or peritoneum and eight high-grade appendiceal adenocarcinoma metastatic to peritoneum were performed using oligonucleotide microarray.
  • RESULTS: In an unsupervised hierarchical cluster analysis of 2-fold upregulated or downregulated genes, there was a clear site-specific segregation of liver versus peritoneal metastases.
  • Subsets of genes significantly associated with poor survival were defined, a RET proto-oncogene interacting gene, GOLGA5, was highly predictive for survival in patients with colorectal adenocarcinoma.
  • CONCLUSIONS: These results demonstrate that liver and peritoneal metastases of lower GI adenocarcinoma have distinct gene expression patterns; these distinctions may help in the development of therapies based on site of metastases.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. Gene Expression Profiling. Liver Neoplasms / genetics
  • [MeSH-minor] Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / secondary. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899288.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


67. Ko S, Chu KM, Luk JM, Wong BW, Yuen ST, Leung SY, Wong J: CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach. J Pathol; 2005 Apr;205(5):615-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach.
  • CDX2 and liver-intestine (LI)-cadherin are intestine-specific markers and both are physiologically expressed in the small intestine and colon.
  • Overexpression of CDX2 was significantly associated with CDH17 in gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cadherins / metabolism. Homeodomain Proteins / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Metaplasia / metabolism. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Neoplasm Staging. Precancerous Conditions / metabolism. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Stomach / pathology. Up-Regulation

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732140.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDH17 protein, human; 0 / CDX2 protein, human; 0 / Cadherins; 0 / Homeodomain Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


68. Hori T, Wagata T, Takemoto K, Shigeta T, Takuwa H, Hata K, Uemoto S, Yokoo N: Spontaneous necrosis of solid gallbladder adenocarcinoma accompanied with pancreaticobiliary maljunction. World J Gastroenterol; 2008 Oct 14;14(38):5933-7
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for gallbladder adenocarcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous necrosis of solid gallbladder adenocarcinoma accompanied with pancreaticobiliary maljunction.
  • We were agonized in making the qualitative diagnosis of mass-like lesions of the fundus, such as a benign tumor, cancer, or debris.
  • Although this necrotic nodule included non-viable adenocarcinoma cells, viable cancer cell nests were located in the muscularis propria and subcutaneous layer.
  • Histopathological examination confirmed a solid adenocarcinoma.
  • We therefore undertook radical surgery, including wedge resection of the liver, radical dissection of regional lymph nodes, and resection of the extrahepatic bile duct.
  • We present the first case of spontaneous necrosis of solid gallbladder adenocarcinoma, with a review of previous studies.
  • [MeSH-major] Adenocarcinoma / pathology. Biliary Tract / abnormalities. Gallbladder Neoplasms / pathology. Incidental Findings. Pancreas / abnormalities
  • [MeSH-minor] Aged. Cholangiography. Cholecystectomy, Laparoscopic. Cholecystitis, Acute / surgery. Fatal Outcome. Gallstones / surgery. Humans. Lymph Node Excision. Magnetic Resonance Imaging. Male. Necrosis. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2006 Mar;32(2):208-12 [16377119.001]
  • [Cites] Vnitr Lek. 2004 Oct;50(10):781-5 [15633935.001]
  • [Cites] Am J Surg. 2007 Sep;194(3):355-61 [17693282.001]
  • [Cites] J Gastrointest Surg. 2007 Sep;11(9):1188-93 [17712596.001]
  • [Cites] Postgrad Med J. 2000 Feb;76(892):96-8 [10644387.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):631-5 [10919001.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(1):95-100 [11294297.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):340-8 [11466688.001]
  • [Cites] World J Surg. 2002 Jul;26(7):867-71 [11960212.001]
  • [Cites] Ann Surg Oncol. 2003 May;10(4):447-54 [12734095.001]
  • [Cites] Cancer. 1983 Dec 1;52(11):2086-8 [6627217.001]
  • [Cites] Surg Gastroenterol. 1984;3(2):69-73 [6085899.001]
  • [Cites] Ann Surg. 1992 Apr;215(4):326-31 [1558412.001]
  • [Cites] Eur J Endocrinol. 1994 May;130(5):469-71 [8180674.001]
  • [Cites] Hepatogastroenterology. 1995 Apr;42(2):113-6 [7545638.001]
  • [Cites] Br J Urol. 1995 Oct;76(4):501-3 [7551893.001]
  • [Cites] Surg Endosc. 1997 Dec;11(12):1224-5 [9373301.001]
  • [Cites] Am J Clin Pathol. 1998 Jan;109(1):62-8 [9426519.001]
  • [Cites] Cancer Invest. 1998;16(1):64-5 [9474255.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):423-7 [9690533.001]
  • [Cites] Am Surg. 1998 Aug;64(8):764-7 [9697909.001]
  • [Cites] J Clin Endocrinol Metab. 1953 Aug;13(8):997-1008 [13069604.001]
  • [Cites] World J Gastroenterol. 2006 Apr 28;12(16):2549-55 [16688800.001]
  • (PMID = 18855999.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 25
  • [Other-IDs] NLM/ PMC2751910
  •  go-up   go-down


69. Shrikhande SV, Kleeff J, Reiser C, Weitz J, Hinz U, Esposito I, Schmidt J, Friess H, Büchler MW: Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol; 2007 Jan;14(1):118-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic resection for M1 pancreatic ductal adenocarcinoma.
  • BACKGROUND: Improved safety of pancreatic surgery has led to consideration of more aggressive approaches, such as resection for primary pancreatic ductal adenocarcinoma (PDAC) with metastatic disease (M1).
  • METHODS: A total of 29 patients who underwent pancreatic resection with resection of associated metastatic disease (interaortocaval lymph node dissection, liver resection, and/or multiorgan resections) were retrospectively identified from a database of 316 R0/R1 pancreatic resections for PDAC.
  • The median survival in those with metastatic interaortocaval lymph nodes was 27 months (95% CI, 9.6-27.0), whereas it was 11.4 months (95% CI, 7.8-16.5) and 12.9 months (95% CI, 7.2-20.5) for those with liver and peritoneal metastases, respectively.
  • Resection of liver and peritoneal metastases, although safe in this series, cannot be generally recommended until further controlled trials can be conducted.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Pancreatic Ductal / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066229.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Welsh JS, Kennedy AS, Thomadsen B: Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. Int J Radiat Oncol Biol Phys; 2006;66(2 Suppl):S62-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma.
  • INTRODUCTION: Selective internal radiation therapy (SIRT) is a relatively new commercially available microbrachytherapy technique for treatment of malignant hepatic lesions using (90)Y embedded in resin microspheres, which are infused directly into the hepatic arterial circulation.
  • It is FDA approved for liver metastases secondary to colorectal carcinoma and is under investigation for treatment of other liver malignancies, such as hepatocellular carcinoma and neuroendocrine malignancies.
  • Toxicity is usually mild, featuring fatigue, anorexia, nausea, abdominal discomfort, and slight elevations of liver function tests.
  • CONCLUSIONS: Selective internal radiation therapy represents an effective means of controlling liver metastases from colorectal adenocarcinoma.
  • Investigations of SIRT for other hepatic malignancies and in combination with newer chemotherapy agents and targeted biologic therapies are under way or in planning.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Colorectal Neoplasms. Liver Neoplasms / radiotherapy. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Algorithms. Cell Hypoxia. Humans. Liver / radiation effects. Microspheres. Radiation Injuries / etiology. Radiotherapy Dosage. Technetium Tc 99m Aggregated Albumin

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979443.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Technetium Tc 99m Aggregated Albumin; 0 / Yttrium Radioisotopes
  • [Number-of-references] 70
  •  go-up   go-down


71. An JY, Kim JY, Choi MG, Noh JH, Choi D, Sohn TS, Kim S: Radiofrequency ablation for hepatic metastasis from gastric adenocarcinoma. Yonsei Med J; 2008 Dec 31;49(6):1046-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation for hepatic metastasis from gastric adenocarcinoma.
  • The prognosis for gastric cancer with liver metastasis continues to be poor.
  • We present our preliminary findings from 4 cases of liver metastasis from gastric adenocarcinomas treated using radiofrequency ablation (RFA).
  • Between 1995 and 2004, the clinical history and course of 4 patients who underwent radiofrequency ablation for liver metastases from gastric cancer were reviewed.
  • Although this study was limited to a few cases and had a short follow-up duration, our findings suggest that RFA may provide an alternative treatment modality for liver metastasis resulting from gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Catheter Ablation / methods. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterol Clin Biol. 1999 Nov;23(11):1128-33 [10651531.001]
  • [Cites] Surg Gynecol Obstet. 1989 Oct;169(4):371-85 [2476864.001]
  • [Cites] Surg Today. 2000;30(11):1041-5 [11110405.001]
  • [Cites] Am J Surg. 2001 Mar;181(3):279-83 [11376587.001]
  • [Cites] Radiology. 2001 Oct;221(1):159-66 [11568334.001]
  • [Cites] Ann Surg. 2002 Jan;235(1):86-91 [11753046.001]
  • [Cites] Arch Surg. 2002 Apr;137(4):422-6; discussion 427 [11926946.001]
  • [Cites] Hepatogastroenterology. 2002 Jul-Aug;49(46):1062-5 [12143202.001]
  • [Cites] J Gastrointest Surg. 2002 Sep-Oct;6(5):682-9 [12399057.001]
  • [Cites] Surgery. 2003 May;133(5):507-11 [12773978.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1560-3 [14571786.001]
  • [Cites] Am J Surg. 1980 Sep;140(3):356-9 [6158880.001]
  • [Cites] Hepatogastroenterology. 1997 May-Jun;44(15):897-900 [9222711.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Oct;31(11):1737-9 [15553699.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):459-66 [15886903.001]
  • [Cites] Am Surg. 2005 Feb;71(2):95-9 [16022005.001]
  • [Cites] Ann Ital Chir. 2005 Jan-Feb;76(1):39-41 [16035670.001]
  • [Cites] Semin Radiat Oncol. 2005 Oct;15(4):265-72 [16183480.001]
  • [Cites] J Vasc Interv Radiol. 2005 Dec;16(12):1747-51 [16371545.001]
  • [Cites] World J Gastroenterol. 2005 Oct 28;11(40):6395-401 [16419172.001]
  • [Cites] AJR Am J Roentgenol. 2000 Dec;175(6):1619-25 [11090390.001]
  • (PMID = 19108032.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2628018
  •  go-up   go-down


72. Voutsadakis IA, Doumas S, Tsapakidis K, Papagianni M, Papandreou CN: Bone and brain metastases from ampullary adenocarcinoma. World J Gastroenterol; 2009 Jun 7;15(21):2665-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone and brain metastases from ampullary adenocarcinoma.
  • Ampullary carcinoma is the second most common cancer of the peri-ampullary area after pancreatic carcinoma and metastasizes mostly intra-abdominally and to the liver.
  • In this report we describe the case of a patient with resected adenocarcinoma of the ampulla of Vater who developed skeletal metastases in the lower extremity and brain metastases.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater / pathology. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Common Bile Duct Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreas. 2006 May;32(4):390-5 [16670621.001]
  • [Cites] Clin Exp Metastasis. 2005;22(7):587-91 [16475029.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(6):549-55 [17139430.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):50-60 [17054003.001]
  • [Cites] World J Surg. 2007 Jan;31(1):137-43; discussion 144-6 [17171495.001]
  • [Cites] Eur J Surg Oncol. 2007 Apr;33(3):346-51 [17097846.001]
  • [Cites] Hepatogastroenterology. 2007 Sep;54(78):1652-4 [18019686.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(1):15-24 [18274840.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(1):41-54 [18274843.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):724-8 [18187485.001]
  • [Cites] BMC Cancer. 2008;8:170 [18547417.001]
  • [Cites] World J Gastroenterol. 2008 Aug 7;14(29):4709-12 [18698690.001]
  • [Cites] BMC Cancer. 2008;8:251 [18761739.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):945-53 [10863064.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):65-9 [11146780.001]
  • [Cites] Hepatogastroenterology. 2002 Jan-Feb;49(43):247-8 [11941966.001]
  • [Cites] Arch Surg. 2003 Sep;138(9):941-8; discussion 948-50 [12963649.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1176-83 [14654474.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):223-31 [15368105.001]
  • [Cites] J Urol. 1996 Nov;156(5):1765 [8863596.001]
  • [Cites] Br J Surg. 1997 Feb;84(2):198-9 [9052433.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] J Korean Med Sci. 1999 Apr;14(2):220-2 [10331573.001]
  • [Cites] JOP. 2004 Nov;5(6):495-7 [15536289.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(5):301-9 [15549428.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1811-8 [15774774.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):588-94 [15832081.001]
  • [Cites] Tumori. 2005 Mar-Apr;91(2):206-9 [15948555.001]
  • [Cites] Arch Surg. 2005 Jun;140(6):529-32; discussion 532-3 [15967899.001]
  • [Cites] Indian J Gastroenterol. 2005 Sep-Oct;24(5):222-3 [16361773.001]
  • [Cites] World J Surg. 2006 Jun;30(6):985-91 [16736326.001]
  • (PMID = 19496199.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2691500
  •  go-up   go-down


73. Ahmed SI, Bochkarev V, Oleynikov D, Sasson AR: Patients with pancreatic adenocarcinoma benefit from staging laparoscopy. J Laparoendosc Adv Surg Tech A; 2006 Oct;16(5):458-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with pancreatic adenocarcinoma benefit from staging laparoscopy.
  • Very often, peritoneal small liver metastases and true local status cannot be fully determined without surgery.
  • The aim of this study was to determine the impact of laparoscopy in patients with potentially resectable adenocarcinoma of the pancreas.
  • [MeSH-major] Adenocarcinoma / surgery. Laparoscopy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004868.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Sahani DV, Kalva SP, Fischman AJ, Kadavigere R, Blake M, Hahn PF, Saini S: Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. AJR Am J Roentgenol; 2005 Jul;185(1):239-46
Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET.
  • OBJECTIVE: The objective of our study was to assess the relative performance of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET for the detection of liver metastases from adenocarcinoma of the colon and pancreas.
  • MATERIALS AND METHODS: Imaging data of 34 patients (23 men, 11 women; age range, 44-78 years) with adenocarcinoma of the colon (n = 27) or adenocarcinoma of the pancreas (n = 7) who had undergone mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET were retrospectively reviewed for the presence and number of liver metastases.
  • RESULTS: Thirty patients had hepatic metastases and four had no hepatic metastases according to the standard of reference.
  • MRI detected more hepatic metastases than FDG PET (p = 0.016).
  • CONCLUSION: In patients with colon and pancreatic adenocarcinoma, high-spatial-resolution mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET were comparable in the detection of patients with liver metastases.
  • However, significantly more and smaller liver metastases were detected on MRI than on FDG PET.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / pathology. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15972430.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 42Z2K6ZL8P / Manganese; 5V5IOJ8338 / Pyridoxal Phosphate; 9G34HU7RV0 / Edetic Acid; P28BIW0UTB / N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid
  •  go-up   go-down


75. Klopfleisch R, van der Grinten E, Gruber AD: Metastatic uterine adenocarcinoma and hepatic lipomatosis in a llama (Lama glama). J Vet Diagn Invest; 2009 Mar;21(2):280-2
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic uterine adenocarcinoma and hepatic lipomatosis in a llama (Lama glama).
  • Postmortem examination revealed an infiltrative uterine adenocarcinoma with widespread metastases.
  • The neoplasm completely replaced and infiltrated the myometrium of the uterine body and cervix and metastasized largely to the serosal surfaces of the peritoneal cavity.
  • [MeSH-major] Adenocarcinoma / veterinary. Camelids, New World. Lipomatosis / veterinary. Papillomaviridae / isolation & purification. Papillomavirus Infections / veterinary. Uterine Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19286516.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Viral Proteins
  •  go-up   go-down


76. Jahan M, Xiao P, Go A, Cheema M, Hameed A: Intraductal and invasive adenocarcinoma of duct of Luschka, mimicking chronic cholecystitis and cholelithiasis. World J Surg Oncol; 2009;7:4
MedlinePlus Health Information. consumer health - Gallstones.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal and invasive adenocarcinoma of duct of Luschka, mimicking chronic cholecystitis and cholelithiasis.
  • BACKGROUND: Intraductal and invasive adenocarcinoma of duct of Luschka is rare.
  • Ultrasound examination revealed thickening of gallbladder wall with abnormal septation around liver bed.
  • Patient underwent laparoscopic cholecystectomy and resection of the adjacent liver bed.
  • Histologic examination confirmed an intraductal and invasive adenocarcinoma arising from Luschka ducts.
  • CONCLUSION: Adenocarcinoma of ducts of Luschka should be considered among differential diagnoses for the patients with typical clinical presentations of chronic cholecystitis and cholelithiasis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Bile Duct Neoplasms / diagnosis. Cholecystectomy, Laparoscopic. Cholecystitis / diagnosis. Cholelithiasis / diagnosis
  • [MeSH-minor] Adult. Chronic Disease. Diagnosis, Differential. Female. Humans. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Cholecystitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(5):494-8 [11702263.001]
  • [Cites] AJR Am J Roentgenol. 2003 Mar;180(3):694-6 [12591676.001]
  • [Cites] World J Surg. 2006 Jul;30(7):1316-20 [16830216.001]
  • [Cites] Surg Radiol Anat. 1991;13(3):203-11 [1754955.001]
  • [Cites] Surg Endosc. 1994 Mar;8(3):193-6 [8191357.001]
  • [Cites] Br J Surg. 1989 Jul;76(7):696-8 [2765803.001]
  • (PMID = 19128463.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2631453
  •  go-up   go-down


77. Riles WL, Erickson J, Nayyar S, Atten MJ, Attar BM, Holian O: Resveratrol engages selective apoptotic signals in gastric adenocarcinoma cells. World J Gastroenterol; 2006 Sep 21;12(35):5628-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resveratrol engages selective apoptotic signals in gastric adenocarcinoma cells.
  • AIM: To investigate the intracellular apoptotic signals engaged by resveratrol in three gastric adenocarcinoma cancer cell lines, two of which (AGS and SNU-1) express p53 and one (KATO-III) with deleted p53.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Stilbenes / pharmacology. Stomach Neoplasms / pathology
  • [MeSH-minor] Caspases / genetics. Caspases / metabolism. Cell Line, Tumor. Electron Transport Complex IV / genetics. Electron Transport Complex IV / metabolism. Fas-Associated Death Domain Protein / genetics. Fas-Associated Death Domain Protein / metabolism. Gene Expression Regulation, Neoplastic / drug effects. Humans. Inhibitor of Apoptosis Proteins. Microtubule-Associated Proteins / genetics. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. RESVERATROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2000 Apr;31(4):922-31 [10733549.001]
  • [Cites] Cell Biol Int. 2001;25(4):331-8 [11319839.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1633-9 [11577002.001]
  • [Cites] J Clin Invest. 2001 Oct;108(7):991-9 [11581300.001]
  • [Cites] Biochem Pharmacol. 2001 Nov 15;62(10):1423-32 [11709203.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):615-22 [11745454.001]
  • [Cites] N Engl J Med. 2002 Jan 3;346(1):65-7 [11778008.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3247-57 [11714700.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 May;282(5):G809-16 [11960777.001]
  • [Cites] Ann N Y Acad Sci. 2002 May;957:210-29 [12074974.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):91-7 [12085263.001]
  • [Cites] Cancer Lett. 2003 Feb 20;190(2):157-63 [12565170.001]
  • [Cites] BMC Cancer. 2002 Oct 17;2:27 [12383351.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7724-32 [14633697.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 26;312(4):1178-84 [14651997.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):337-46 [14729643.001]
  • [Cites] Mol Cancer Ther. 2004 Jan;3(1):71-84 [14749477.001]
  • [Cites] J Altern Complement Med. 2004 Apr;10(2):235-9 [15165403.001]
  • [Cites] Gastroenterol Jpn. 1987 Aug;22(4):419-27 [2444485.001]
  • [Cites] Science. 1997 Jan 10;275(5297):218-20 [8985016.001]
  • [Cites] Science. 1997 Mar 14;275(5306):1649-52 [9054359.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1808-12 [9581817.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):435-44 [9690535.001]
  • [Cites] Carcinogenesis. 1999 Feb;20(2):237-42 [10069459.001]
  • [Cites] Biochem Pharmacol. 1998 May 1;55(9):1339-46 [10076523.001]
  • [Cites] Drugs Exp Clin Res. 1999;25(2-3):87-97 [10370869.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] World J Gastroenterol. 2005 Jan 14;11(2):280-4 [15633232.001]
  • [Cites] Invest New Drugs. 2005 Mar;23(2):111-9 [15744586.001]
  • [Cites] Cell Death Differ. 2000 Sep;7(9):834-42 [11042678.001]
  • (PMID = 17007014.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / BIRC5 protein, human; 0 / Fas-Associated Death Domain Protein; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Stilbenes; 0 / Tumor Suppressor Protein p53; EC 1.9.3.1 / Electron Transport Complex IV; EC 3.4.22.- / Caspases; Q369O8926L / resveratrol
  • [Other-IDs] NLM/ PMC4088162
  •  go-up   go-down


78. Sasaki Y, Natsuizaka M, Takano M, Suzuki M, Tsuyuguchi M, Nagasako T, Kawamura N, Kudo M, Tsuda I, Meguro J: [A case of primary adenocarcinoma of small intestine with multiple liver metastases successfully treated with mFOLFOX6]. Gan To Kagaku Ryoho; 2009 Nov;36(11):1927-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary adenocarcinoma of small intestine with multiple liver metastases successfully treated with mFOLFOX6].
  • Biopsy of the tumor was performed and pathological examination revealed adenocarcinoma.
  • CT also showed multiple liver metastases.
  • Histopathological examination revealed moderately-differentiated adenocarcinoma of Bauhin's valve and the terminal ileum, and no adenocarcinoma was found in the cecum and ascending colon.
  • He was diagnosed with primary adenocarcinoma of the ileum with multiple liver metastases.
  • After 5 courses of chemotherapy, abdominal CT showed marked regression of the liver metastases, and tumor marker (CA19-9) was normalized from 1,100 U/mL to 36 U/mL.
  • Effectiveness of mFOLFOX6 for primary adenocarcinoma of small intestine is suggested.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ileal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19920403.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


79. Molenaar JP, Baten A, Blokx WA, Hoogendam A: Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate. Eur Urol; 2009 Nov;56(5):874-7; quiz 876
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate.
  • We present the case of an 81-yr-old man with a prostatic adenocarcinoma and a metastatic carcinoid.
  • Simultaneous occurrence of hormonally treated adenocarcinoma of the prostate and a carcinoid has been described before.
  • The pathogenesis of this coincidence is largely unclear; however, androgen deprivation therapy might play a key role in neuroendocrine differentiation of adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Anilides / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Carcinoid Tumor / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary. Nitriles / therapeutic use. Prostatic Neoplasms / drug therapy. Tosyl Compounds / therapeutic use
  • [MeSH-minor] Aged, 80 and over. Biopsy. Humans. Male. Malignant Carcinoid Syndrome / drug therapy. Positron-Emission Tomography. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19171417.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Tosyl Compounds; 51110-01-1 / Somatostatin; A0Z3NAU9DP / bicalutamide
  •  go-up   go-down


80. Kripp M, Ströbel P, Dinter D, Lukan N, Hochhaus A, Hofheinz RD: Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin. Anticancer Drugs; 2009 Jan;20(1):75-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin.
  • Alpha-fetoprotein-producing metastatic adenocarcinoma of the stomach or the esophago-gastric junction usually exhibits either no or only short-term remission while receiving palliative chemotherapy.
  • We report on a 76-year-old male patient suffering from an unresectable alpha-fetoprotein-producing adenocarcinoma of the esophago-gastric junction with several liver metastases.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Esophageal Neoplasms / drug therapy. Esophagogastric Junction / pathology. Liver Neoplasms / drug therapy. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19343004.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / alpha-Fetoproteins; 0W860991D6 / Deoxycytidine; U3P01618RT / Fluorouracil; XELOX
  •  go-up   go-down


81. Lu CC, De-Chuan C, Lee HS, Chu HC: Pure hepatoid adenocarcinoma of the stomach with spleen and lymph-node metastases. Am J Surg; 2010 Apr;199(4):e42-4
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure hepatoid adenocarcinoma of the stomach with spleen and lymph-node metastases.
  • The authors report a rare case of hepatoid adenocarcinoma of the stomach, presenting initially with spleen and lymph node metastases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cardia. Liver Neoplasms / diagnosis. Lymph Nodes / pathology. Splenic Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20359564.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins; 8001-40-9 / Iodized Oil; 80168379AG / Doxorubicin
  •  go-up   go-down


82. Alver O, Ersoy YE, Dogusoy G, Erguney S: Primary umbilical adenocarcinoma: case report and review of the literature. Am Surg; 2007 Sep;73(9):923-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary umbilical adenocarcinoma: case report and review of the literature.
  • Primary adenocarcinoma arising at the umbilicus is a very rare condition.
  • Herein, we describe a case of a primary umbilical adenocarcinoma with short time survival related to local recurrence and multiple hepatic metastases 6 months after her surgical treatment.
  • [MeSH-major] Abdominal Neoplasms / pathology. Adenocarcinoma / pathology. Umbilicus / pathology
  • [MeSH-minor] Fatal Outcome. Female. Humans. Liver Neoplasms / secondary. Middle Aged. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17939428.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


83. Vesić S, Daković Z, Vukićević J, Vuković J, Stojković J, Medenica L: [Dermatomyositis associated with metastatic rectal adenocarcinoma: case report]. Med Pregl; 2009 Sep-Oct;62(9-10):473-5
Genetic Alliance. consumer health - Dermatomyositis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dermatomyositis associated with metastatic rectal adenocarcinoma: case report].
  • Association of dermatomyositis with malignant conditions has been described in various studies.
  • We present a patient with paraneoplastic dermatomyositis associated with metastatic rectal adenocarcinoma.
  • According to the medical documents and history, he underwent surgery because of rectal adenocarcinoma in April 2006.
  • The diagnosis of dermatomyositis was based on: characteristic clinical picture; the elevated serum level of following enzymes: creatinine kinase, lactate dehydrogenase; the presence of anti-Mi 2 antibodies in serum; electromyographic finding; and by histology of the muscle biopsy.
  • Paraneoplastic nature of dermatomyositis was confirmed by computer tomography of the abdomen which revealed multiple deposits in the liver, by explorative laparotomy showing peritoneal dissemination and histopathological analysis that verified metastatic adenocarcinoma of the rectum.
  • CONCLUSION: We report a case of paraneoplastic dermatomyositis associated with metastatic rectal adenocarcinoma and lethal outcome, and suggest a comprehensive evaluation of patients with dermatomyositis older than 50 years in order to exclude or verify the occult malignancy.
  • [MeSH-major] Adenocarcinoma / secondary. Dermatomyositis / complications. Paraneoplastic Syndromes / complications. Rectal Neoplasms / complications
  • [MeSH-minor] Aged. Humans. Liver Neoplasms / complications. Liver Neoplasms / secondary. Male. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20391745.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


84. Barshack I, Meiri E, Rosenwald S, Lebanony D, Bronfeld M, Aviel-Ronen S, Rosenblatt K, Polak-Charcon S, Leizerman I, Ezagouri M, Zepeniuk M, Shabes N, Cohen L, Tabak S, Cohen D, Bentwich Z, Rosenfeld N: Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression. Int J Biochem Cell Biol; 2010 Aug;42(8):1355-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression.
  • Distinguishing hepatocellular carcinoma from metastatic tumors in the liver is of great practical importance, with significant therapeutic and prognostic implications.
  • This differential diagnosis can be difficult because metastatic cancers in the liver, especially adenocarcinomas, may mimic the morphology and immunoexpression of hepatocellular carcinoma.
  • Biomarkers that are specifically expressed in either hepatocellular carcinoma or metastatic adenocarcinoma can therefore be useful diagnostic tools.
  • Hsa-miR-141 and hsa-miR-200c, microRNAs that promote epithelial phenotypes, had significantly higher levels in non-hepatic epithelial tumors.
  • Combinations of these microRNAs accurately identified primary hepatocellular carcinoma from metastatic adenocarcinoma in the liver.
  • Thus, the tissue-specific expression patterns of microRNAs make them useful biomarkers for the diagnosis of liver malignancies.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / genetics. Gene Expression Regulation, Neoplastic. Liver / metabolism. Liver Neoplasms / diagnosis. Liver Neoplasms / genetics. MicroRNAs / genetics
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Metastasis. ROC Curve. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20619223.001).
  • [ISSN] 1878-5875
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


85. Chiba N, Yoshioka T, Sakayori M, Mikami Y, Miyazaki S, Akiyama S, Otsuka K, Yamaura G, Shibata H, Kato S, Kato S, Ishioka C: AFP-producing hepatoid adenocarcinoma in association with Barrett's esophagus with multiple liver metastasis responding to paclitaxel/CDDP: a case report. Anticancer Res; 2005 Jul-Aug;25(4):2965-8
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AFP-producing hepatoid adenocarcinoma in association with Barrett's esophagus with multiple liver metastasis responding to paclitaxel/CDDP: a case report.
  • A case of alpha-fetoprotein (AFP)-producing hepatoid adenocarcinoma in association with Barrett's esophagus with multiple liver metastases, responding to chemotherapy, is reported.
  • A 47-year-old man was admitted to our hospital with abdominal pain after subtotal esophagectomy for an esophageal adenocarcinoma in association with Barrett's esophagus, and was diagnosed as having multiple liver tumors.
  • Since microscopic examination of the resected tumor showed a poorly-differentiated adenocarcinoma with hepatoid features displaying AFP-immunoreactivity, the liver tumors were thus considered to be metastatic deposits.
  • This is the first report, to our knowledge, of effective chemotherapy for liver metastases from an AFP-producing hepatoid adenocarcinoma of the esophagus.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Barrett Esophagus / drug therapy. Esophageal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. alpha-Fetoproteins / biosynthesis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Anticancer Res. 2006 Jul-Aug;26(4b):3203. Yoshiki, Mikami [corrected to Mikami, Yoshiki]
  • (PMID = 16080552.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


86. Norris WE, Perry JL, Moawad FJ, Horwhat JD: An unusual presentation of metastatic esophageal adenocarcinoma presenting as thigh pain. J Gastrointestin Liver Dis; 2009 Sep;18(3):371-4
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of metastatic esophageal adenocarcinoma presenting as thigh pain.
  • The association between esophageal adenocarcinoma and distant skeletal muscle metastasis is extremely rare.
  • Endoscopic biopsy showed poorly differentiated adenocarcinoma.
  • Final diagnosis was primary esophageal adenocarcinoma with distant metastasis to the right ileum and iliacus muscle.
  • We review distinctions between esophageal adenocarcinoma and adenocarcinoma of the gastroesophageal junction.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Muscle, Skeletal / pathology. Pain / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19795036.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


87. Chansri N, Kawakami S, Yamashita F, Hashida M: Inhibition of liver metastasis by all-trans retinoic acid incorporated into O/W emulsions in mice. Int J Pharm; 2006 Sep 14;321(1-2):42-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of liver metastasis by all-trans retinoic acid incorporated into O/W emulsions in mice.
  • All-trans retinoic acid (ATRA) was incorporated into lipid emulsions in an attempt to alter its distribution characteristics and improve its inhibition of liver cancer metastasis.
  • After intravenous administration in mice, [3H]cholesteryl hexadecyl ether incorporated into emulsion, which is the inherent distribution of emulsions, accumulated gradually mainly in the liver.
  • The blood concentration and hepatic accumulation of [3H]ATRA incorporated into emulsion was significantly higher than that of serum dissolving [3H]ATRA, which represent the original distribution characteristic of free ATRA.
  • In a murine liver metastasis model by colon adenocarcinoma, the liver metastasis number and liver weight were significantly reduced and the survival time of mice was prolonged following intravenous injection of ATRA incorporated into emulsions.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Liver Neoplasms, Experimental / prevention & control. Liver Neoplasms, Experimental / secondary. Tretinoin / administration & dosage

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16790329.001).
  • [ISSN] 0378-5173
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Emulsions; 5688UTC01R / Tretinoin; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


88. Liu KT, Chan HM, Lin TJ: An unusual presentation of metastatic gastric adenocarcinoma--acute onset of right neck swelling. J Formos Med Assoc; 2007 Jul;106(7):589-91
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of metastatic gastric adenocarcinoma--acute onset of right neck swelling.
  • Fluid accumulation over deep neck space led to the diagnosis of suspected hemorrhage, and central venous thrombosis was found by computed tomography.
  • Elevated serum tissue polypeptide antigen and CA130 were noted, and multiple liver metastases were found by another computed tomography.
  • Subsequently, gastric adenocarcinoma was confirmed after gastroendoscopy.
  • Gastric adenocarcinoma with distal metastases was finally diagnosed.
  • Malignancy, including gastric adenocarcinoma, is one of the causes that should be considered.

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660150.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


89. Kim JH, Choi EK, Yoon HK, Ko GY, Sung KB, Gwon DI: Transcatheter arterial chemoembolization for hepatic recurrence after curative resection of pancreatic adenocarcinoma. Gut Liver; 2010 Sep;4(3):384-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcatheter arterial chemoembolization for hepatic recurrence after curative resection of pancreatic adenocarcinoma.
  • BACKGROUND/AIMS: Despite curative resection, hepatic recurrences cause a significant reduction in survival in patients with primary pancreatic adenocarcinoma.
  • Transcatheter arterial chemoembolization (TACE) has recently been used successfully to treat primary and secondary hepatic malignancy.
  • METHODS: Between 2003 and 2008, 15 patients underwent TACE because of hepatic recurrence after curative resection of a pancreatic adenocarcinoma.
  • The remaining five patients demonstrated continued progression of hypovascular hepatic lesions.
  • The median survival periods from the time of diagnosis and from the time of initial TACE were 9.6 and 7.5 months, respectively.
  • CONCLUSIONS: TACE may represent a viable therapeutic modality in patients with hepatic recurrence after curative resection of pancreatic adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20981218.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2956353
  • [Keywords] NOTNLM ; Liver / Pancreatic adenocarcinoma / Transcatheter arterial chemoembolization
  •  go-up   go-down


90. Greenlee JE, Clawson SA, Hill KE, Dechet CB, Carlson NG: Antineuronal autoantibodies in paraneoplastic cerebellar degeneration associated with adenocarcinoma of the prostate. J Neurol Sci; 2010 Apr 15;291(1-2):74-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antineuronal autoantibodies in paraneoplastic cerebellar degeneration associated with adenocarcinoma of the prostate.
  • Paraneoplastic neurological syndromes are unusual in prostatic cancer, and paraneoplastic cerebellar degeneration associated with adenocarcinoma of the prostate is rare.
  • Here we report a 68year old man who developed progressive ataxia in the setting of stage D2 adenocarcinoma of the prostate and whose MRI showed cerebellar atrophy.
  • The patient's serum produced a previously undescribed pattern of immunoreactivity, binding to nuclei and cytoplasm of Purkinje cells, deep cerebellar neurons, scattered cells in the molecular and granule cell layers, and neuronal populations in thalamus, cerebral cortex, and hippocampus but not with liver or kidney.
  • Sera from neurologically normal patients with adenocarcinoma of the prostate did not contain this antibody, and the patient's serum did not react with normal prostate or with prostatic adenocarcinomas from other individuals.
  • Prostatic adenocarcinoma may occasionally be accompanied by development of anticerebellar antibodies.
  • Adenocarcinoma of the prostate should be considered as a possible underlying malignancy in older males with unexplained progressive cerebellar degeneration.
  • [MeSH-major] Adenocarcinoma / immunology. Autoantibodies / blood. Brain / immunology. Neurons / immunology. Paraneoplastic Cerebellar Degeneration / immunology. Prostatic Neoplasms / immunology

  • Genetic Alliance. consumer health - Cerebellar Degeneration.
  • Genetic Alliance. consumer health - Paraneoplastic cerebellar degeneration.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier B.V.
  • (PMID = 20089262.001).
  • [ISSN] 1878-5883
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Autoantibodies
  •  go-up   go-down


91. Kant P, Sahay P: Varicoid adenocarcinoma of the esophagus: case report. Dysphagia; 2008 Jun;23(2):205-7
MedlinePlus Health Information. consumer health - Varicose Veins.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Varicoid adenocarcinoma of the esophagus: case report.
  • We present only the second reported case of a patient with varicoid adenocarcinoma of the esophagus.
  • In the absence of chronic liver disease, we advocate that variceal lesions within the esophagus should be regarded with a high index of suspicion for possible varicoid esophageal cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagus / blood supply. Varicose Veins / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18058174.001).
  • [ISSN] 0179-051X
  • [Journal-full-title] Dysphagia
  • [ISO-abbreviation] Dysphagia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Chapman C, Aboulafia DM, Dezube BJ, Pantanowitz L: Human immunodeficiency virus-associated adenocarcinoma of the colon: clinicopathologic findings and outcome. Clin Colorectal Cancer; 2009 Oct;8(4):215-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency virus-associated adenocarcinoma of the colon: clinicopathologic findings and outcome.
  • BACKGROUND: Patients infected with Human immunodeficiency virus (HIV) living longer with antiretroviral therapy (ART) are more likely to develop non-AIDS-defining cancers such as adenocarcinoma of the colon.
  • There have been limited case reports regarding HIV-associated colon adenocarcinoma.
  • The aim of this study was to characterize the clinicopathologic findings and outcome in a series of HIV-infected patients diagnosed and treated for colon adenocarcinoma.
  • PATIENTS AND METHODS: A retrospective study involving HIV-related colon adenocarcinoma was performed.
  • Most carcinomas (57%) involved the right colon, were largely TNM stage 4 cancers (47%), and, when present, metastases were mainly to the liver.
  • Many (47%) individuals died within 1-26 months after their cancer diagnosis.
  • Immunosuppression (AIDS diagnosis and/or CD4+ < 500 cells/mm3) did not appear to correlate with tumor grade, stage, or an adverse outcome.
  • CONCLUSION: These data show that HIV-infected patients with adenocarcinoma of the colon tend to be young men with a high incidence of right-sided involvement.
  • [MeSH-major] Adenocarcinoma / complications. Colonic Neoplasms / complications. HIV Infections / complications

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822512.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Djuranovic SP, Spuran MM, Kovacevic NV, Ugljesic MB, Kecmanovic DM, Micev MT: Mucinous cystadenoma of the appendix associated with adenocarcinoma of the sigmoid colon and hepatocellular carcinoma of the liver: report of a case. World J Gastroenterol; 2006 Mar 28;12(12):1975-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous cystadenoma of the appendix associated with adenocarcinoma of the sigmoid colon and hepatocellular carcinoma of the liver: report of a case.
  • This condition is often associated with other neoplasia, especially adenocarcinoma of the colon and ovaries.
  • He had a big cystadenoma of the appendix associated with adenocarcinoma of the colon and hepatocellular carcinoma of the liver.
  • The patient underwent right haemicolectomy, sigmoid colon resection and segmental resection of the liver.
  • According to this, we stress the need of accurate preoperative diagnosis and intraoperative exploration of the whole abdomen in these patients.
  • [MeSH-major] Adenocarcinoma / complications. Appendiceal Neoplasms / complications. Carcinoma, Hepatocellular / complications. Cystadenoma, Mucinous / complications. Liver Neoplasms / complications. Sigmoid Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2000 Apr;43(4):559-60 [10789759.001]
  • [Cites] Dis Colon Rectum. 2001 Jul;44(7):1034-6 [11496084.001]
  • [Cites] Curr Surg. 2003 May-Jun;60(3):341-3 [14972272.001]
  • [Cites] Cancer. 1973 Dec;32(6):1525-41 [4757938.001]
  • [Cites] Am J Gastroenterol. 1992 Jun;87(6):787-9 [1590322.001]
  • [Cites] Surg Endosc. 2003 May;17(5):833-4 [15768456.001]
  • [Cites] J Chir (Paris). 1994 Jun-Jul;131(6-7):303-12 [7844184.001]
  • [Cites] Am J Gastroenterol. 1997 May;92(5):898-9 [9149213.001]
  • [Cites] Am J Gastroenterol. 1997 Oct;92(10):1920-2 [9382067.001]
  • [Cites] Abdom Imaging. 1998 May-Jun;23(3):292-6 [9569300.001]
  • [Cites] Radiographics. 1998 Jul-Aug;18(4):1049-50 [9672990.001]
  • [Cites] AJR Am J Roentgenol. 1992 Jul;159(1):69-72 [1609724.001]
  • (PMID = 16610012.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087531
  •  go-up   go-down


94. D'Angelica M, Dalal KM, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR: Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol; 2009 Apr;16(4):806-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the extent of resection for adenocarcinoma of the gallbladder.
  • The objective of this study was to analyze the impact of the extent of resection for gallbladder adenocarcinoma on disease-specific survival (DSS) and perioperative morbidity.
  • Analysis of a prospective hepatobiliary surgery database identified patients undergoing surgical resection for gallbladder adenocarcinoma from 1990 to 2002.
  • Twenty-one patients (20%) underwent en bloc resection of adjacent organs other than the liver.
  • Major hepatic resections, including major hepatectomy and CBD excision, are appropriate when necessary to clear disease but are not mandatory in all cases.
  • [MeSH-major] Adenocarcinoma / surgery. Bile Duct Neoplasms / surgery. Gallbladder Neoplasms / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2009 Aug;16(8):2084-5 [19506960.001]
  • [CommentIn] Ann Surg Oncol. 2009 Apr;16(4):787-8 [19165545.001]
  • (PMID = 18985272.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Xie YB, Zhao P, Wang CF, Shan Y, Zhao DB, Liu Q, Bai XF: [Analysis of factors influencing recurrence and metastasis following curative resection of pancreatic ductal adenocarcinoma]. Zhonghua Zhong Liu Za Zhi; 2008 Sep;30(9):686-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of factors influencing recurrence and metastasis following curative resection of pancreatic ductal adenocarcinoma].
  • OBJECTIVE: To investigate the factors influencing recurrence and metastasis following curative resection of pancreatic ductal adenocarcinoma and analyze the prognosis.
  • METHODS: The clinicopathological and follow-up data of 56 patients who underwent curative resection for pancreatic ductal adenocarcinoma between Jan.
  • Hepatic metastasis and local recurrence accounted for 36.6% and 31.7% of the cases, respectively.
  • CONCLUSION: The metastasis or recurrence mostly occurs within 2 years after curative resection, and the liver is the most common site of metastasis.
  • [MeSH-minor] Adult. Aged. CA-19-9 Antigen / metabolism. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pancreatectomy / methods. Proportional Hazards Models. Retrospective Studies. Survival Rate. Tumor Burden

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173911.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


96. Bacigalupo L, Aufort S, Eberlé MC, Assenat E, Ychou M, Gallix B: Assessment of liver metastases from colorectal adenocarcinoma following chemotherapy: SPIO-MRI versus FDG-PET/CT. Radiol Med; 2010 Oct;115(7):1087-100
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of liver metastases from colorectal adenocarcinoma following chemotherapy: SPIO-MRI versus FDG-PET/CT.
  • PURPOSE: This study compared superparamagnetic iron-oxide-enhanced magnetic resonance imaging (SPIO-MRI) and combined fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) in evaluating liver metastases from colorectal adenocarcinoma following chemotherapy.
  • CONCLUSIONS: SPIO-MRI appears superior to PET/CT in evaluating liver metastases from colorectal adenocarcinoma following chemotherapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Contrast Media. Ferrosoferric Oxide. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Magnetic Resonance Imaging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20574703.001).
  • [ISSN] 1826-6983
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; XM0M87F357 / Ferrosoferric Oxide
  •  go-up   go-down


97. Sato K, Imai T, Shirota Y, Ueda Y, Katsuda S: Combined large cell neuroendocrine carcinoma and adenocarcinoma of the gallbladder. Pathol Res Pract; 2010 Jun 15;206(6):397-400
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined large cell neuroendocrine carcinoma and adenocarcinoma of the gallbladder.
  • Large cell neuroendocrine carcinoma (LCNEC) is a high-grade malignant neuroendocrine tumor that was first defined in the lungs.
  • We describe a tumor combined with LCNEC and adenocarcinoma elements arising in the gallbladder and give a review of the literature.
  • A 68-year-old woman was diagnosed as having gallbladder wall thickening and a hepatic mass.
  • The surgically resected tumor had a dumbbell shape with gallbladder and liver elements.
  • Histological examination revealed LCNEC in the liver and a deep infiltrative portion of the gallbladder, as well as a well-differentiated tubular adenocarcinoma in the mucosa of the gallbladder.
  • The results suggest a close relationship between LCNEC and adenocarcinoma, and support the theory that these elements originate from common cancer stem cells.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Large Cell / pathology. Carcinoma, Neuroendocrine / pathology. Gallbladder Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19945229.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Chromogranin A; 0 / Synaptophysin
  • [Number-of-references] 15
  •  go-up   go-down


98. Kim ST, Lee J, Lee KT, Lee JK, Lee KH, Choi SH, Heo JS, Choi DW, Park SH, Park JO, Lim HY, Park YS, Kang WK: The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater. Med Oncol; 2010 Dec;27(4):1149-54
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.
  • Adenocarcinoma arising from the ampulla of Vater is a rare neoplasm that accounts for only 0.2% of all gastrointestinal tract malignancies and has limited data regarding its frontline therapy.
  • We investigated the treatment outcomes in patients with advanced adenocarcinoma of the ampulla of Vater receiving frontline cisplatin-based combination chemotherapy.
  • We analyzed 29 patients with advanced adenocarcinoma of the ampulla of Vater who had been treated by frontline cisplatin-based combination chemotherapy between June 2003 and April 2008.
  • The cisplatin-based combination chemotherapy showed moderate activity and a favorable toxicity profile as a frontline treatment for patients with advanced adenocarcinoma of the ampulla of Vater.
  • [MeSH-major] Adenocarcinoma / drug therapy. Ampulla of Vater / drug effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Common Bile Duct Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Capecitabine. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / secondary. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898973.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


99. Zhang S, Wang M, Xue YH, Chen YP: Cerebral metastasis from hepatoid adenocarcinoma of the stomach. World J Gastroenterol; 2007 Nov 21;13(43):5787-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral metastasis from hepatoid adenocarcinoma of the stomach.
  • We first report a rare case of metastasis from gastric hepatoid adenocarcinoma (HAC) to cerebral parenchyma, in a 50-year-old Chinese patient.
  • Three years ago, the patient accepted total gastrectomy as he was pathologically diagnosed at gastroscopy having an adenocarcinoma.
  • Eight months after gastrectomy, the occupying lesion in liver was detected by ultrasound and CT, and he accepted transcatheter arterial embolization.
  • Before operation of the brain metastasis, no obvious abnormality was found in liver by ultrasound.
  • Immunohistochemistry-stained tumor cells were positive for AFP and negative for Hep-Par-1.
  • The differential diagnosis of brain metastasis from metastatic tumors should use a panel of antibodies to avoid confusing with the brain metastasis of hepatocellular carcinoma (HCC).
  • This paper describes this rare case of metastasis from gastric hepatoid adenocarcinoma to cerebral parenchyma, and provides a review of the literature concerning its histopathological and immunohistochemical characteristics.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Hepatocellular / diagnosis. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17963312.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4171272
  •  go-up   go-down


100. An M, Shin JA, Lee SM, Yoon T, Park WS, Choi JI, Kim CM: [Liver metastasis of colon cancer with a high serum alpha-fetoprotein level: report of a case]. Korean J Hepatol; 2006 Dec;12(4):562-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver metastasis of colon cancer with a high serum alpha-fetoprotein level: report of a case].
  • We report herein a case of 72-year-old woman in whom liver metastasis of colon cancer was presented with a marked elevation of serum alpha-fetoprotein (AFP) level.
  • She was transferred to our hospital for multiple liver masses found on ultrasonogram.
  • Abdominal computed tomogram revealed multiple low-density masses in the liver and wall thickening of the hepatic flexure of colon.
  • Colonoscopic findings of ulcerofungating mass suggested liver metastasis from colon cancer.
  • Both colon and liver biopsies revealed moderately differentiated tubular adenocarcinoma.
  • Using an immunohistochemical staining, the adenocarcinoma in liver showed focal positive to AFP, but not in colon.
  • [MeSH-major] Colonic Neoplasms / pathology. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237635.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down






Advertisement